Live Events
Live Events
7:00 PM EDT
GLP-1 RAs
The Contemporary Use of GLP-1 RAs to Individualize Therapy in T2DM: Candid Conversations on Glycemic and Nonglycemic Effects
James R. Gavin III, MD, PhD
Healing Our Village, Inc.
Emory University School of Medicine
Atlanta, Georgia
7:00 PM EDT
Gastric and GEJ Cancer
Redrawing the Algorithm in Gastric and GEJ Cancers: Treatment Planning and Sequencing in the Era of Immunotherapy
Manish A. Shah, MD, FASCO
Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine
Weill Cornell Medicine/New York-Presbyterian Hospital
New York, New York
7:00 PM EDT
Venous Thromboembolism (VTE)
Reducing the Global Burden of Cancer-Associated VTE: Applying Guideline-Concordant, Evidence-Based Care & Shared Decision-Making Strategies to Improve Patient Outcomes
Alok A. Khorana, MD, FACP, FASCO
Taussig Cancer Institute
Cleveland Clinic Lerner School of Medicine
Case Western Reserve University
Cleveland, Ohio
Robert D. McBane, II, MD
Mayo Clinic Gonda Vascular Center
Rochester, Minnesota
7:00 PM EDT
B-Cell Cancers
The Next Building Block for B-Cell Cancer Care: Exploring Personalized Treatment With Emerging BTK Inhibitor Options in CLL/SLL and MCL
Anthony R. Mato, MD, MSCE
Memorial Sloan Kettering Cancer Center
New York, New York
7:00 PM EDT
Psoriasis
Taking Aim at the TYK2 Pathway in Psoriasis: Addressing Unmet Treatment and Patient Needs With an Innovative Therapeutic Approach
April W. Armstrong, MD, MPH
Southern California Clinical and Translational Science Institute (SC CTSI)
Keck School of Medicine
University of Southern California
Los Angeles, California
Kenneth B. Gordon, MD
Medical College of Wisconsin
Milwaukee, Wisconsin
7:00 PM EDT
NSCLC
Maximizing the Potential of Immunotherapy in Multimodal Management of Unresectable Stage III NSCLC: Collaboration Is Crucial, Patient Selection Is Paramount, Close Monitoring Is Critical
Stephen V. Liu, MD
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, District of Columbia
6:15 AM CDT
Chronic Lymphocytic Leukemia
Seizing the Day With BTK Inhibitors in CLL: Evidence-Informed Therapy Selection, Safety, and Sequential Care
Nicole Lamanna, MD
Herbert Irving Comprehensive Cancer Center
New York-Presbyterian/Columbia University Medical Center
New York, New York
Jennifer Woyach, MD
The Ohio State University
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio
6:30 AM CDT
Myelofibrosis
Understanding the Clinical Spectrum of Myelofibrosis: Expert Perspectives on Molecular Biology, JAK Inhibitors, and Emerging Therapeutics
Srdan Verstovsek, MD, PhD
The University of Texas MD Anderson Cancer Center
Houston, Texas
Ruben A. Mesa, MD, FACP
Mays Cancer Center at UT Health San Antonio MD Anderson
San Antonio, Texas
5:00 PM EDT
Non–Small Cell Lung Cancer
Harnessing the Potential of HER2-, HER3-, and TROP2-Targeted Therapies to Address Unmet Needs in Advanced NSCLC
Melissa L. Johnson, MD
Sarah Cannon Research Institute
Nashville, Tennessee
7:00 PM EDT
Multiple Myeloma
Breaking Therapeutic Barriers in RRMM: Team-Based Solutions for Integrating Novel Antibody Platforms and Improving Myeloma Care
Sagar Lonial, MD, FACP
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia
5:00 PM CDT
Immuno-Oncology Biomarkers
Evolving Standards in Biomarker Testing, Scoring, and Results Interpretation Driven by the Broadening Role of Cancer Immunotherapy
Kurt A. Schalper, MD, PhD
Assistant Professor of Pathology and Medical Oncology
Yale School of Medicine
Director, Translational Immuno-Oncology Laboratory
Yale Cancer Center
New Haven, Connecticut
7:00 PM EDT
Colorectal Cancer
Putting a Personalized Colorectal Cancer Treatment Algorithm Into Practice: Applying Evidence and Navigating Practicalities in the Era of Molecularly Defined Care Using Novel Targeted, Immune, and Cytotoxic Agents
Prof Eric Van Cutsem, MD, PhD
University of Leuven
Leuven, Belgium
6:00 PM PDT
Eosinophilic Esophagitis
Fulfilling a Need in the Management of Patients With Eosinophilic Esophagitis: An Exploration of Novel and Emerging Therapeutic Options
Evan S. Dellon, MD, MPH
UNC Center for Esophageal Diseases and Swallowing (CEDAS)
University of North Carolina School of Medicine
Chapel Hill, North Carolina
6:30 PM CDT
Pan Tumor
Implementing Synergistic Multimodal Approaches With Tumor Treating Fields to Extend Survival in Aggressive Cancers
Erik P. Sulman, MD, PhD
NYU Grossman School of Medicine
Laura and Isaac Perlmutter Cancer Center
New York, New York
7:00 AM EDT
Immune-Related Adverse Events
Maintaining Vigilance to Mitigate Cancer Immunotherapy-Related Toxicities in the Emergency Department: Be Aware, Stay Alert, and Change Your Practice
Mark M. Awad, MD, PhD
Lowe Center for Thoracic Oncology
Harvard Medical School
Boston, Massachusetts
Christopher Baugh, MD, MBA
Brigham and Women’s Hospital
Harvard Medical School
Boston, Massachusetts
7:00 AM EDT
Multiple Sclerosis
Exploring the Convergence of Advances in S1P Receptor Modulation With Progress in Understanding Brain Atrophy and Cognition Measures in Multiple Sclerosis
Bruce Cree, MD, PhD, MAS
UCSF Weill Institute for Neurosciences
University of California San Francisco
San Francisco, California
7:00 PM EDT
Multiple Sclerosis
Bruton Tyrosine Kinase Inhibitors for MS: Progress in the Development of an Emerging Therapeutic Approach
Benjamin M. Greenberg, MD, MHS
University of Texas Southwestern Medical Center
Dallas, Texas
Professor Anthony Traboulsee, MD
The MS Society
The University of British Columbia
Vancouver, British Columbia, Canada
12:30 PM EDT
NSCLC
Time for Even More Precision in Testing and Treatment of EGFR-Mutated NSCLC: Refining and Expanding Best Practices in Advanced and Early-Stage Disease Settings
Lynette M. Sholl, MD
Brigham and Women’s Hospital
Harvard Medical School
Boston, Massachusetts
6:05 PM EDT
Small Cell Lung Cancer
Translating Science, Transforming Practice, and Making Headway Toward Better Outcomes in SCLC: Immunotherapy Has Changed the Game, but Where Do We Go Next?
Jonathan W. Goldman, MD
UCLA Jonsson Comprehensive Cancer Center
Ronald Reagan UCLA Medical Center
UCLA Health - Santa Monica Medical Center
Santa Monica, California
7:00 PM EDT
7:00 PM EST
NSCLC
Adjuvant EGFR-Targeted Therapy as a Game Changer: How to Implement New Standards of Care in Multimodal Management of Stage I-III EGFR-Mutated NSCLC
David R. Jones, MD
Memorial Sloan Kettering Cancer Center
New York, New York
12:30 PM EDT
Atopic Dermatitis
Expert Insights From Around the Globe on Tailoring Treatment for Patients With Atopic Dermatitis
Emma Guttman-Yassky, MD, PhD
Icahn School of Medicine
Mount Sinai Medical Center
New York, New York
7:00 PM EDT
7:00 PM EST
Esophageal/GEJ Cancer
Immunotherapy at the Cutting Edge in Resectable Esophageal/GEJ Cancer: Preparing Thoracic Surgeons and the Broader Multidisciplinary Team to Navigate Changing Standards of Care
Ronan J. Kelly, MD, MBA
Director of the Charles A. Sammons Cancer Center at Baylor University Medical Center, Dallas, Texas
Chief of Oncology, Baylor Scott & White Health System (NTx)
W.W. Caruth Jr. Chair of Immunology at Baylor University Medical Center
Clinical Professor, Texas A&M University College of Medicine
Adjunct Associate Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland
Professor, Clinical Sciences Division at the Translational Genomics Research Institute
Phoenix, Arizona
Daniela Molena, MD
Director, Esophageal Surgery Program
Memorial Sloan Kettering Cancer Center
New York, New York
9:00 PM EDT
Renal Cell Carcinoma
Selecting and Sequencing Targeted and Immunotherapy Regimens for RCC: How Will the Latest Evidence Impact Treatment Decisions for My Patients?
Sumanta Kumar Pal, MD, FASCO
City of Hope Comprehensive Cancer Center
Duarte, California
7:00 PM EDT
7:00 PM EST
NSCLC
Has Immunotherapy Brought Us to an Inflection Point in the Multimodal Management of Stage I-III NSCLC? Dissecting the Data and Instituting Multidisciplinary Alliances to Improve Outcomes in Early-Stage Disease
Stephen R. Broderick, MD, MPHS
Johns Hopkins University School of Medicine
Johns Hopkins Kimmel Cancer Center
Baltimore, Maryland
Heather A. Wakelee, MD
Stanford Cancer Center
Stanford, California
5:30 PM EST
Interstitial Lung Disease
Covering All the Bases in SSc-ILD Care: Expert Strategies for Diagnosis, Treatment, and Managing Comorbidities
Lorinda Chung, MD, MS
Stanford University School of Medicine
Palo Alto, California
7:00 PM EST
7:00 PM EST
Breast Cancer
Raising the Bar in HR+/HER2- Early Breast Cancer: Multidisciplinary Strategies for Integrating the CDK4 and 6 Inhibitors
Joyce O’Shaughnessy, MD
Baylor University Medical Center
Dallas, Texas
7:00 PM EST
Obesity
Gut Feeling: The Increasing Importance of GLP-1–Based Therapies for Personalized Obesity Management
Domenica M. Rubino, MD
Washington Center for Weight Management and Research
Arlington, Virginia
Donna H. Ryan, MD, FTOS
Pennington Biomedical Research Center
Baton Rouge, Louisiana
7:00 PM EST
Interstitial Lung Disease
Covering All the Bases in SSc-ILD Care: Expert Strategies for Diagnosis, Treatment, and Managing Comorbidities
Lorinda Chung, MD, MS
Stanford University School of Medicine
Palo Alto, California
6:30 AM EST
Hypertrophic Cardiomyopathy
Making New Strides in Hypertrophic Cardiomyopathy: The Latest Guidelines, Science, and Strategies for Early Diagnosis and Tailored Treatment
Neal K. Lakdawala, MD
Brigham and Women’s Hospital
Harvard Medical School
Boston, Massachusetts
Anjali Tiku Owens, MD
University of Pennsylvania Perelman School of Medicine
Philadelphia, Pennsylvania
8:30 AM EST
7:00 PM EST
HCC/Liver Cancer
Harmonizing HCC Care With a Multidisciplinary Ensemble: Guidance for the Era of Novel Locoregional, Multimodal, and Systemic Strategies
Amit Singal, MD, MS
Professor of Medicine
Willis C. Maddrey Chair in Liver Disease
Chief of Hepatology and Medical Director of the Liver Tumor Program
UT Southwestern Medical Center
Dallas, Texas
5:00 PM EST
Cardiac irAEs
Improving the Detection and Management of Cardiac Immune-Related Adverse Events in Patients With Cancer Is a Must: Are You Prepared?
Javid Moslehi, MD
UCSF School of Medicine
Cardiovascular Research Institute (CVRI)
San Francisco, California
7:00 PM EST
HIV
Parallel Perspectives: A Unique Look at HIV Treatment Decisions From the Provider and the Patient
David Malebranche, MD, MPH
Internal Medicine Physician
Atlanta, Georgia
Peter Shalit, MD, PhD
University of Washington
Seattle, Washington
12:45 PM EST
Glioblastoma
A New Wave of Progress in Glioblastoma: Expert Guidance on Delivering Modern Personalized Care With Tumor Treating Fields and Novel Systemic Approaches
Steven Brem, MD
Penn Brain Tumor Center
Perelman School of Medicine
Abramson Cancer Center, University of Pennsylvania
Philadelphia, Pennsylvania
5:45 PM EST
Bladder Cancer
Breaking Down the Evidence in Bladder Cancer: Expert Perspectives and Practical Strategies on Immune, Targeted, and Antibody-Based Therapies
Petros Grivas, MD, PhD
University of Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington
7:00 AM EST
Prostate Cancer
Personalizing and Advancing Modern Treatment Approaches to Prostate Cancer
Robert Dreicer, MD, MS, MACP, FASCO
University of Virginia Cancer Center
Paul Mellon Urologic Cancer Institute
University of Virginia School of Medicine
Charlottesville, Virginia
Pedro C. Barata, MD, MSc
Tulane University Medical School
New Orleans, Louisiana
8:00 AM EST
Hyperkalemia
Advancing the Standard of Care for Patients With Hyperkalemia: Insights and Evidence for Clinical Pharmacy Practice
George L. Bakris, MD
American Heart Association Comprehensive Hypertension Center
University of Chicago Medicine
Chicago, Illinois
Joanna Hudson, PharmD, BCPS, FASN, FCCP, FNKF
The University of Tennessee Health Science Center
Memphis, Tennessee
8:30 PM EST
Breast Cancer
Personalizing Treatment Decisions in HER2-Altered Breast Cancer: Strategies for Improving Equity and Patient Outcomes Through Individualized Targeted Therapy Selection, Team-Based Care, and Shared Decision-Making
Joyce O’Shaughnessy, MD
Baylor University Medical Center
Dallas, Texas
7:00 AM EST
Follicular Lymphoma
A Better Blend for Follicular Lymphoma: How Targeted, Epigenetic, and Immune Therapies Are Changing Patient Care
Nathan H. Fowler, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas
7:30 AM EST
Chronic Lymphocytic Leukemia (CLL)
Customizing Care in CLL With BTK Inhibitors: Evidence and Applications for Therapy Selection, Sequencing, and Safety Management
John C. Byrd, MD
University of Cincinnati College of Medicine
Cincinnati, Ohio
7:30 AM EST
Multiple Myeloma
A Is for Antibody in Multiple Myeloma: Practical Insights and Patient Voices Along the Therapeutic Journey
Suzanne Lentzsch, MD, PhD
Columbia University Medical Center
New York, New York
7:30 AM EST
Diffuse Large B-Cell Lymphoma
Taking the Turn to Treatment Innovation in DLBCL: Real-World Insight on Integrating Antibodies and Cellular Therapy Into Patient Care
Grzegorz (Greg) Nowakowski, MD
Mayo Clinic
Rochester, Minnesota
7:30 AM EST
Acute Myeloid Leukemia
Seizing Opportunity in AML: How to Realize the Potential of Novel Therapeutics in Diverse Patient Populations
Naval Daver, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas
7:30 AM EST
6:30 PM EST
Sickle Cell Disease
The Evolution of Sickle Cell Disease: Current Advances and Future Possibilities
Biree Andemariam, MD
University of Connecticut Health
Farmington, Connecticut
10:00 AM EST
Eosinophilic Esophagitis
Expert Perspectives on Improving Early Recognition of Eosinophilic Esophagitis and Examining the Potential Clinical Utility of Emerging Targeted Therapy
Chris A. Liacouras, MD
The Children's Hospital of Philadelphia
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania
7:00 PM EST
Hyperkalemia
Advancing the Standard of Care for Patients With Hyperkalemia: Insights and Evidence for Clinical Pharmacy Practice
George L. Bakris, MD
American Heart Association Comprehensive Hypertension Center
University of Chicago Medicine
Chicago, Illinois
Joanna Hudson, PharmD, BCPS, FASN, FCCP, FNKF
The University of Tennessee Health Science Center
Memphis, Tennessee
6:30 PM PST
Hepatocellular Carcinoma
Mapping the Optimal Treatment Route in HCC: Identifying Best Practices in an Expanding Therapeutic Landscape
Richard S. Finn, MD
David Geffen School of Medicine at UCLA
Los Angeles, California
6:15 PM PST
Billiary Cancers
Embracing the Era of Individualized Therapy in Advanced Biliary Cancers: Expert Strategies for Applying New and Emerging Targeted Treatment Options Through Precision Medicine
Milind Javle, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas
1:30 PM EST
NSCLC
Bringing Precision Oncology to Early-Stage Lung Cancer, With Adjuvant EGFR-Targeted Therapy Leading the Way: What Thoracic Surgeons Need to Know and Do
Boris Sepesi, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas
Tina Cascone, MD, PhD
The University of Texas MD Anderson Cancer Center
Houston, Texas
1:00 PM EST
NSCLC
Can the Addition of Immunotherapy to Multimodal Management of Stage I-III NSCLC Help Break the Stalled Cycle of Poor Outcomes?
Nasser Altorki, MD
Weill Cornell Medicine
Meyer Cancer Center of Weill Cornell
New York, New York
Jonathan D. Spicer, MD, PhD, FRCSC
McGill University
Montreal General Hospital
Montreal, Quebec, Canada
7:00 PM CST
Stroke
Mastering the Use of Dual Antiplatelet Therapy for Preventing Recurrent Stroke: How Well Do Your Current Strategies Match With the Experts?
Gregory W. Albers, MD
Stanford University
Stanford Stroke Center
Stanford, California
S. Claiborne “Clay” Johnston, MD, PhD
Dell Medical School
The University of Texas at Austin
Austin, Texas
7:00 PM PST
Renal Cell Carcinoma
Navigating Evolving Standards of Care in Renal Cell Carcinoma: Expert Insights on Selecting and Sequencing Targeted and Immunotherapy Options and a Look at Emerging Strategies
Sumanta Kumar Pal, MD, FASCO
City of Hope Comprehensive Cancer Center
Duarte, California
7:00 PM PST
Bladder Cancer
Achieving State-of-the-Art Care in Bladder Cancer in an Era of Innovative Therapeutic Solutions
Petros Grivas, MD, PhD
University of Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington
6:30 PM PST
Prostate Cancer
Decisions and Dilemmas in Prostate Cancer Management: Building on Progress to Advance Personalized Care Through Candid Conversations and Expert Clinical Consults
Robert Dreicer, MD, MS, MACP, FASCO
University of Virginia Comprehensive Cancer Center
Paul Mellon Urologic Cancer Institute
University of Virginia School of Medicine
Charlottesville, Virginia
3:05 PM PST
6:30 PM EST
NSCLC
Addressing Key Targets in Advanced NSCLC: Evaluating the Latest Evidence and Clinical Opportunities for HER2-, HER3-, and TROP2-Targeted Therapies
Pasi A. Jänne, MD, PhD
Lowe Center for Thoracic Oncology
Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts
7:00 PM EST
NSCLC
Can the Addition of Immunotherapy to Multimodal Management of Stage I-III NSCLC Help Break the Stalled Cycle of Poor Outcomes?
Nasser Altorki, MD
Weill Cornell Medicine
Meyer Cancer Center of Weill Cornell
New York, New York
Jonathan D. Spicer, MD, PhD, FRCSC
McGill University
Montreal General Hospital
Montreal, Quebec, Canada
7:00 PM EST
NSCLC
Bringing Precision Oncology to Early-Stage Lung Cancer, With Adjuvant EGFR-Targeted Therapy Leading the Way: What Thoracic Surgeons Need to Know and Do
Boris Sepesi, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas
Tina Cascone, MD, PhD
The University of Texas MD Anderson Cancer Center
Houston, Texas
7:00 PM EST
7:00 PM EST
Multiple Sclerosis
Rationale, Evidence, and Practical Potential for BTK Inhibitors in Patient-Centered MS Care: Where We Stand Now
Amit Bar-Or, MD, FRCPC
Center for Neuroinflammation and Experimental Therapeutics
Perelman Center for Advanced Medicine (PCAM)
University of Pennsylvania
Philadelphia, Pennsylvania
Daniel S. Reich, MD, PhD
National Institute of Neurological Disorders and Stroke
National Institutes of Health*
Bethesda, Maryland
*Participation in this CME event as an "outside activity"
7:00 AM MST
Severe Asthma
Taking It From the Top: Targeting a New Approach to Controlling Severe Asthma
Purvi S. Parikh, MD, FACP, FACAAI
New York University School of Medicine
New York, New York
Cedric "Jamie" Rutland, MD
American Lung Association
Rutland Medical Group
UCR School of Medicine
Newport Beach, California
7:15 PM CST
Melanoma
Linking Immunotherapy to Better Outcomes in Resectable Melanoma: Guidance on Integrating Immune-Based Adjuvant and Neoadjuvant Options
Jennifer Wargo, MD, MMSc
The University of Texas MD Anderson Cancer Center
Houston, Texas
5:15 PM CST
Breast Cancer
Translating Progress With Immunotherapies and Targeted Agents Into Improved Outcomes in Triple-Negative Breast Cancer: Surgical and Clinical Perspectives on Modern Multimodal Treatment Approaches
Henry M. Kuerer, MD, PhD, FACS
The University of Texas MD Anderson Cancer Center
Houston, Texas
Heather L. McArthur, MD, MPH
UT Southwestern Medical Center
Dallas, Texas
3:00 PM MST
Ovarian Cancer
When Are PARP Inhibitors the Best Choice for Patients With Ovarian Cancer? Personalizing Therapeutic Selection Across the Disease Continuum
Bradley J. Monk, MD, FACS, FACOG
University of Arizona College of Medicine
Creighton University School of Medicine
GOG-Foundation
Phoenix, Arizona
6:15 AM PDT
Immuno-Oncology Biomarkers
Progress and Practicalities in Immunotherapy Biomarker Testing and Pathologic Response Assessment in Solid Tumors: What’s New and What You Need to Know and Do
Kurt A. Schalper, MD, PhD
Yale School of Medicine
Yale Cancer Center
New Haven, Connecticut
6:15 AM PDT
HER2/HER3/TROP2 Testing/Treatment
Decoding the Latest Evidence and Practical Recommendations on Biomarker Testing for New Therapeutic Options Targeting HER2, HER3, and TROP2 in Solid Tumors
Kurt A. Schalper, MD, PhD
Yale School of Medicine
Yale Cancer Center
New Haven, Connecticut
7:00 PM EDT
Cancer Screening
Cancer Screening and Preventive Care for Transgender Individuals: Patient and Provider Perspectives on Best Practices and Special Considerations
Elizabeth Eaman, MD
Oodle Family Medicine
Renton, Washington
Healthy Transitions, LLC
Montclair, New Jersey
University of Washington
Seattle, Washington
7:00 PM EDT
T2DM and Obesity
Is Synergism the Secret to Success? Candid Conversations on Targeting GIP and GLP-1 to Individualize Treatment in Patients With T2DM and Obesity
Javier Morales, MD, FACP, FACE
Donald and Barbara Zucker School of Medicine
Hofstra Northwell Hempstead
Advanced Internal Medicine Group, PC
East Hills, New York
6:30 AM PDT
PARP Inhibitors
Expanding the Benefits of PARP Inhibitor Therapy to More Patients With Breast Cancer and Earlier Disease Settings: Multidisciplinary Perspectives on How to Maximize the Potential of PARP Inhibitors and Optimize Their Use as Part of Multimodal Management of Breast Cancer
Henry M. Kuerer, MD, PhD, FACS
The University of Texas MD Anderson Cancer Center
Houston, Texas
7:00 PM CDT
Cancer Immunotherapy
Parsing the Practicalities of Pathologic Response Assessment After Neoadjuvant Immunotherapy to Facilitate Progress in Early-Stage Cancers
Prof. Solange Peters, MD, PhD
University Hospital of Lausanne
Lausanne, Switzerland
6:00 PM CDT
Ovarian Cancer
Making Sense of The Evolving Treatment Landscape in Ovarian Cancer Care: Pharmacy Perspectives on PARP Inhibitor Therapy
Thomasina Morris, RPh, MHA, BCOP
Moffitt Cancer Center
Tampa, Florida
7:00 PM EDT
7:00 PM EDT
NSCLC
Expanding Options, Lingering Questions: How to Select the Right Immunotherapy for First-Line Treatment of Advanced NSCLC
Mark A. Socinski, MD
AdventHealth Cancer Institute
Orlando, Florida
12:15 PM PDT
Solid Tumors
Tackling the Practicalities of Antibody–Drug Conjugate Therapy for Solid Tumors: Improving Clinical Care With HER2-, HER3-, and TROP2-Targeted Therapies
Linda Ahn, MSN, ANP-BC, AOCNP
Memorial Sloan Kettering Cancer Center
New York, New York
6:00 AM PDT
Chronic Lymphocytic Leukemia
Hope Is Here in CLL: Oncology Nurse Strategies for Delivering Effective, Compassionate, and Modern Care to Patients
Amy Goodrich, CRNP
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland
6:00 PM PDT
Renal Cell Carcinoma
Aligning Nursing Care Strategies With Evolving Patient Needs in RCC: Interprofessional Insights on Optimizing Outcomes With Novel Targeted and Immune-Based Therapies
Nancy P. Moldawer, RN, MSN
Cedars-Sinai Medical Center
Los Angeles, California
7:30 AM EDT
Neurofibromatosis
Revolutionizing the Standard of NF1 Care: Insights on Innovative MEK-Inhibitor Options for NF1-Associated PNs
Bruce R. Korf, MD, PhD
UAB School of Medicine
University of Alabama at Birmingham
Birmingham, Alabama
Miriam Bornhorst, MD
Children’s National Hospital
Washington, DC
12:45 PM EDT
Acute Lymphoblastic Leukemia
Adapting to Innovation in Pediatric ALL: Guidance on Optimizing Modern Therapy and the Role of Novel Asparaginase Compounds
Stuart S. Winter, MD
Children's Minnesota
Minneapolis, Minnesota
Reuven Schore, MD
Children’s National Hospital
The George Washington University School of Medicine and Health Sciences
Washington, District of Columbia
12:30 PM EDT
NSCLC
How to Integrate Perioperative Immunotherapy Into Multimodal Treatment Plans to Improve Outcomes in Resectable NSCLC
Nasser Altorki, MD
Weill Cornell Medicine
Meyer Cancer Center of Weill Cornell
New York, New York
Jonathan D. Spicer, MD, PhD, FRCSC
McGill University
Montreal General Hospital
Montreal, Quebec, Canada
6:00 PM CDT
Bladder Cancer
Urology Clinical Consults: Bladder Cancer Cases From the Community—Expert Guidance on Translating the Latest Therapeutic Advances Into Patient Care for Early to Advanced Bladder Cancer
Ashish M. Kamat, MD, MBBS
The University of Texas MD Anderson Cancer Center
Houston, Texas
7:30 PM EDT
Asthma
The Future of Severe Asthma Treatment Is Here: Expert Insights on the Rationale for Targeting Epithelial Alarmins
Reynold A. Panettieri, Jr., MD
Robert Wood Johnson Medical School
Rutgers Institute for Translational Medicine and Science
Rutgers University
New Brunswick, New Jersey
University of Pennsylvania
Eileen Wang, MD, MPH
National Jewish Health
University of Colorado School of Medicine
Denver, Colorado
7:00 AM EDT
Multiple Sclerosis
Innovations and Imaging in Multiple Sclerosis: Examining the Evidence, Looking Toward the Future of Bruton Tyrosine Kinase Inhibitors
Benjamin M. Greenberg, MD, MHS
University of Texas Southwestern Medical Center
Dallas, Texas
Professor Anthony Traboulsee, MD
The MS Society
The University of British Columbia
Vancouver, British Columbia, Canada
7:00 PM CDT
Chronic Lymphocytic Leukemia
Rewriting the Treatment Script in CLL: Guidance on Integrating Modern Targeted and Next-Gen Options Into Patient Care
Anthony R. Mato, MD, MSCE
Memorial Sloan Kettering Cancer Center
New York, New York
7:00 AM EDT
Multiple Sclerosis
Re-Examining S1PR Modulation From All Angles in Relapsing Multiple Sclerosis: Impact on Physical and Cognitive Outcomes, and Practical Considerations of Long-Term Therapy
Bruce Cree, MD, PhD, MAS
UCSF Weill Institute for Neurosciences
University of California San Francisco
San Francisco, California
7:00 PM CDT
Melanoma
New Rules for Sequential Care in BRAF-Mutated Melanoma: Rethinking Upfront Selection and Sequencing of Immunotherapy and Targeted Agents in Metastatic Disease
Hussein A. Tawbi, MD, PhD
The University of Texas
MD Anderson Cancer Center
Houston, Texas
7:00 PM CDT
AML
The Advantage of Innovation in AML: Guidance on Developing and Delivering Effective and Highly Personalized Care
Gail J. Roboz, MD
Weill Cornell Medical College
New York Presbyterian Hospital
New York, New York
7:00 PM CDT
Small Cell Lung Cancer
Assessing the Impact of Therapeutic Advances in SCLC: Instilling New Hope and Moving in Leaps and Bounds Toward Better Outcomes
Jacob Sands, MD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts
7:00 PM CDT
RCC
Refining RCC Management Across the Disease Continuum: An Expert Clinical Consult on Leveraging New Evidence and Novel Therapeutic Strategies to Personalize Patient Care
Toni K. Choueiri, MD
Lank Center for Genitourinary Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts
6:00 AM CDT
DR/DME
A Call to Action for Diabetes Specialists: Your Role in Saving the Eyesight of Patients With Diabetes
Richard Beaser, MD
Joslin Diabetes Center
Harvard Medical School
Boston, Massachusetts
12:30 PM EDT
COVID-19
Do You Know How to Use COVID-19 Monoclonal Antibodies as Pre-Exposure Prophylaxis for Your Post-Transplant Patients? Test Your Knowledge
Shmuel Shoham, MD
Professor of Medicine
Transplant and Oncology Infectious Diseases Program
Division of Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, Maryland
Myron S. Cohen, MD
Yeargan-Bate Eminent Professor of Medicine, Microbiology and Epidemiology
Associate Vice Chancellor for Medical Affairs and Global Health
Director, Institute for Global Health and Infectious Diseases
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
7:00 PM CDT
CAR-T THERAPY
Rising to the Occasion: Improving Outcomes in Leukemia, Lymphoma, and Multiple Myeloma With CAR-T Therapy in Community Practice
Jason Westin, MD, MS, FACP
The University of Texas MD Anderson Cancer Center
Houston, Texas
7:00 PM CDT
HCC/LIVER CANCER
Setting the Course for the Optimal Management of HCC: Improving Patient Outcomes Through the Integration of Novel Therapeutic Approaches Across the Continuum of Care
Richard S. Finn, MD
Professor of Clinical Medicine
Division of Hematology/Oncology
David Geffen School of Medicine at UCLA
Los Angeles, California
7:00 PM CDT
NSCLC
Find the Targets, Treat With Precision: Modern Principles and New Advances in Biomarker-Driven Lung Cancer Care
Stephen V. Liu, MD
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC
7:00 PM CDT
MULTIPLE MYELOMA
The “Myelennial” Generation: Managing the Boom of Innovative Therapy to Transform Myeloma Care and Enhance Patient Outcomes
Nina Shah, MD
UCSF Helen Diller Family Comprehensive Cancer Center
The University of California, San Francisco
San Francisco, California
7:00 PM CDT
HEAD AND NECK CANCER
The Power and Promise of Immunotherapy in Head and Neck Cancer: How Established and Emerging Immune-Based Options Can Enhance Patient Care
Robert I. Haddad, MD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts
7:00 PM CDT
NSCLC
Gaining an Advantage Over NSCLC: How to Achieve the Greatest Benefit With Immunotherapy From Advanced to Early Disease
David P. Carbone, MD, PhD
International Association for the Study of Lung Cancer
James Thoracic Oncology Center
James Cancer Center
The Ohio State University Medical Center
Columbus, Ohio
7:00 PM CDT
MELANOMA
Choosing Innovation With Immunotherapy in Melanoma: Guidance on Utilizing Immune-Based and Other Novel Options in Resectable and Unresectable Disease
Michael B. Atkins, MD
Georgetown-Lombardi Comprehensive Cancer Center
Georgetown University School of Medicine
Washington, District of Columbia
7:00 PM CDT
BASAL CELL CARCINOMA
Immunotherapy Has Arrived in Advanced BCC: Collaborative Strategies for Making the Most of Novel Immune-Based Treatment
Karl D. Lewis, MD
University of Colorado Anschutz Medical Campus
University of Colorado Cancer Center
Aurora, Colorado
7:00 PM CDT
BLADDER CANCER
Blazing the Trail Forward in the Therapeutic Management of Bladder Cancer: Expert Insights on Incorporating the Latest Evidence and Treatment Advancements Into Practice Across the Disease Continuum
Petros Grivas, MD, PhD
University of Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington
7:00 PM CDT
METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
Realizing the Potential of Novel Treatment Intensification Strategies for Metastatic Castration-Sensitive Prostate Cancer: The Experts’ Take on Key Clinical Evidence, Practical Considerations, and Best Practices for Individualized, Patient-Centered Care
Matthew R. Smith, MD, PhD
Harvard Medical School
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
12:00 PM EDT
HCC/LIVER CANCER
Making Headway Towards Better Outcomes in Intermediate- to Advanced-Stage Hepatocellular Carcinoma: A Multidisciplinary Tumor Board on Implementing Novel Locoregional and Systemic Approaches
Riad Salem, MD, MBA
Northwestern University Feinberg School of Medicine
Chicago, Illinois
7:00 PM EDT
BREAST CANCER
Navigating the Shifting Treatment Paradigm in ER+/HER2- Breast Cancer: Harnessing Modern Treatment Options and the Expanding Evidence Base to Better Patient Care and Outcomes in Early and Advanced Disease
Aditya Bardia, MD, MPH
Massachusetts General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts
13:40 CEST
Gastric Cancer
Realizing Improved Outcomes in HER2-Positive Gastrointestinal Cancers: New Evidence and Practical Guidance With Targeted Agents
Elena Elez, MD, PhD
Vall d’Hebron Institute of Oncology
Barcelona, Spain
Yelena Y. Janjigian, MD
Memorial Sloan Kettering Cancer Center
New York, New York
7:00 PM EDT
Diabetic Macular Edema and Diabetic Retinopathy
A Call to Action for Diabetes Specialists: Your Role in Saving the Eyesight of Patients With Diabetes
Richard Beaser, MD
Joslin Diabetes Center
Harvard Medical School
Boston, Massachusetts
7:00 PM EDT
Basal Cell Carcinoma
Immunotherapy Has Arrived in Advanced BCC: Collaborative Strategies for Making the Most of Novel Immune-Based Treatment
Karl D. Lewis, MD
University of Colorado Anschutz Medical Campus
University of Colorado Cancer Center
Aurora, Colorado
7:00 PM EDT
Nontuberculous Mycobacterial Lung Disease
Confronting the Challenges of Nontuberculous Mycobacterial Lung Disease: Expert Strategies for Reducing Diagnostic Delays and Improving Adherence to Guideline-Based Treatment
Julie V. Philley, MD
University of Texas at Tyler Health Science Center
Tyler, Texas
Kevin Winthrop, MD, MPH
Oregon Health & Science University
Portland, Oregon
12:00 PM EDT
Solid Tumors
Uncovering Gene Fusions & Other Key Genomic Alterations in Lung, Thyroid, Colon, Breast, and Other Solid Tumors to Enable All Patients to Gain the Full Benefits of Targeted Treatment
Alexander Drilon, MD
Memorial Sloan Kettering Cancer Center
New York, New York
6:00 PM CDT
MANTLE CELL LYMPHOMA
Rebooting the BTK Inhibitor Sequence in MCL: Team-Centered Guidance on the Personalized Selection of Covalent and Noncovalent BTK Inhibitors in Relapsed/Refractory Disease
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD
Oxford University Hospitals
NHS Foundation Trust
Oxford, United Kingdom
Nirav Shah, MD, MS
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin
6:45 AM CDT
Small Cell Lung Cancer
Improving Outcomes in SCLC Through Optimal Integration of the Latest Therapies: Expert Perspectives on the State of the Science, Best Practices, Multidisciplinary Care, and Future Directions
Taofeek K. Owonikoko, MD, PhD
University of Pittsburgh
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania
7:30 PM CDT
NSCLC
Are You Prepared for the New Wave of ADCs in NSCLC? Innovative Approaches and Practical Considerations in Targeting HER2, HER3, TROP2, and Other Alterations in Advanced Lung Cancer
Marina Chiara Garassino, MD
University of Chicago Medicine
Chicago, Illinois
6:45 AM CDT
NSCLC
Refining Biomarker Testing and Targeted Treatment of NSCLC With Common and Uncommon EGFR Mutations
Natasha B. Leighl, MD, MMSc, FRCPC, FASCO
Princess Margaret Cancer Centre
PMC Foundation
University of Toronto
Dalla Lana School of Public Health
Toronto, Ontario, Canada
6:00 PM CDT
MYELODYSPLASTIC SYNDROMES
The “Innovation Moment” Arrives for MDS: Guidance on Building Personalized Management Plans to Improve Patient Outcomes
Guillermo Garcia-Manero, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas
Gail J. Roboz, MD
Weill Cornell Medical College
New York Presbyterian Hospital
New York, New York
12:00 PM EDT
ATOPIC DERMATITIS
Using Biologics to Manage Moderate to Severe Atopic Dermatitis: Compare Your Approach With Experts From Around the World
Professor Jacob P. Thyssen
Bispebjerg Hospital
University of Copenhagen
Copenhagen, Denmark
12:41 PM CDT
ACUTE MYELOID LEUKEMIA
The Power of Personalized Medicine in AML: Linking Individualized Treatment to Enhanced Patient Outcomes
Naval Daver, MD
The University of Texas
MD Anderson Cancer Center
Houston, Texas
Amir T. Fathi, MD
Massachusetts General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts
12:41 PM CDT
CHRONIC LYMPHOCYTIC LEUKEMIA
Challenges and Changes With Targeted Options in CLL: Guidance on Making Evidence-Informed Upfront and Sequential Treatment Choices
Nicole Lamanna, MD
Herbert Irving Comprehensive Cancer Center
New York-Presbyterian/Columbia University Medical Center
New York, New York
Deborah M. Stephens, DO
University of Utah/Huntsman Cancer Institute
Salt Lake City, Utah
11:50 AM CDT
MULTIPLE MYELOMA
Progress on the Path to Better Outcomes in RRMM: Expert Perspectives on the Further Integration of BCMA-Directed Antibodies and Cellular Therapies
Sagar Lonial, MD, FACP
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia
Krina Patel, MD, MSc
The University of Texas
MD Anderson Cancer Center
Houston, Texas
7:00 PM EDT
DIABETIC MACULAR EDEMA AND DIABETIC RETINOPATHY
A Call to Action for Primary Care Professionals: Your Role in Saving the Eyesight of Patients With Diabetes
Mark W. Stolar, MD
Feinberg School of Medicine
Northwestern University
Chicago, Illinois
12:30 PM EDT
NSCLC
Precision Decisions in Multimodal Management of Early-Stage NSCLC: Integrating EGFR-Targeted Therapy in Perioperative Settings
Brendon M. Stiles, MD
Montefiore-Einstein Cancer Center
Albert Einstein College of Medicine
Montefiore Medical Center
New York, New York
6:45 PM EDT
NSCLC
Extending Survival and Setting Our Sights on Cure in Resectable NSCLC: Getting the Details of Perioperative Immunotherapy Right
Nasser Altorki, MD
Weill Cornell Medicine
Meyer Cancer Center of Weill Cornell
New York, New York
Jonathan D. Spicer, MD, PhD, FRCSC
McGill University
Montreal General Hospital
Montreal, Quebec, Canada
7:00 PM CDT
MULTIPLE MYELOMA
The Eye-Deal Connection in Multiple Myeloma: Establishing Ophthalmology-Oncology Relationships to Overcome Ocular Toxicity
Praneetha Thulasi, MD
Emory Eye Center
Emory University School of Medicine
Atlanta, Georgia
Jonathan L. Kaufman, MD
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia
6:30 PM EDT
EOSINOPHILIC ESOPHAGITIS
Updates in Eosinophilic Esophagitis: Exploring Underlying Mechanisms and Integrating Novel Targeted Therapy to Improve Patient Care
Sandeep K. Gupta, MD
Community Health Network
Riley Hospital for Children
Indiana University School of Medicine
Indianapolis, Indiana
6:45 AM CDT
ASTHMA
Selecting Targeted Treatment for Pediatric and Adult Patients With Uncontrolled Moderate to Severe Asthma
Leonard B. Bacharier, MD
Monroe Carell Jr. Children’s Hospital at Vanderbilt University Medical Center
Nashville, Tennessee
Monica Kraft, MD
Icahn School of Medicine at Mount Sinai
Mount Sinai Health System
New York, New York
6:30 PM CDT
SOLID TUMORS
Harnessing Novel Synergies With Tumor Treating Fields: Insights on Improving Survival With Multimodal Care in Aggressive Tumors
Erik P. Sulman, MD, PhD
NYU Grossman School of Medicine
Laura and Isaac Perlmutter Cancer Center
New York, New York
7:00 PM CDT
RENAL CELL CARCINOMA
RCC Clinical Consults: Making Difficult Treatment Decisions at the Intersection of the Data and the Real World
Sumanta Kumar Pal, MD, FASCO
City of Hope Comprehensive Cancer Center
Duarte, California
6:30 AM CDT
CARDIAC IRAES
Updating Our Cardio-Oncology Skills in the Cancer Immunotherapy Era: Team-Based Strategies for Risk Assessment, Diagnosis, and Management of Myocarditis and Other Cardiac Immune-Related Adverse Events
Javid Moslehi, MD
UCSF School of Medicine
Cardiovascular Research Institute (CVRI)
San Francisco, California
1:00 PM EDT
HCC/LIVER CANCER
It Takes a Team for HCC: Improving Outcomes Through Multidisciplinary Collaboration & Modern Therapeutics
Amit Singal, MD, MS
UT Southwestern Medical Center
Dallas, Texas
6:00 PM CDT
HEART FAILURE
How I Think, How I Treat: Cardiology-Focused Perspectives on Using SGLT2 Inhibitors to Optimize Outcomes in Patients With Heart Failure
Javed Butler, MD, MPH, MBA
Baylor Scott and White Research Institute
Dallas, Texas
University of Mississippi
Jackson, Mississippi
6:30 AM CST
HYPERLIPIDEMIA
Personalizing the Management of Hyperlipidemia: Addressing Unmet Needs Among High-Risk Patients With Atherosclerotic Cardiovascular Disease With Novel Lipid-Lowering Therapies
Peter H. Jones, MD, MNLA
Center for Cardiometabolic Disease Prevention
Houston Methodist DeBakey Heart and Vascular Center
Baylor College of Medicine
Houston, Texas
R. Scott Wright, MD
Mayo Clinic
Rochester, Minnesota
8:30 PM EST
SEVERE ASTHMA
Leveling the Playing Field for All Patients With Severe Asthma: Directing New Treatment Approaches at the Airway Epithelium
Juan Carlos Cardet, MD
University of South Florida
Tampa, Florida
Geoffrey L. Chupp, MD
Yale School of Medicine
Yale Center for Asthma and Airway Disease
Yale New Haven Hospital
New Haven, Connecticut
12:45 CET
BREAST CANCER
TROP2-Targeting ADCs as New Tools in the TNBC and HR+/HER2- Breast Cancer Treatment Arsenal: Advancing Patient-Centered Care to Make the Most of Modern Targeted Treatments
Professor Peter Schmid, FRCP, MD, PhD
Centre for Experimental Cancer Medicine
Bart's Cancer Institute, Queen Mary University of London
London, England, United Kingdom
5:30 PM EST
GLIOBLASTOMA
Setting Our Sights on Improved Outcomes in Glioblastoma: State-of-the-Art Care With Tumor Treating Fields and Other Innovative Approaches
Steven Brem, MD
Penn Brain Tumor Center
Perelman School of Medicine
Abramson Cancer Center, University of Pennsylvania
Philadelphia, Pennsylvania
1:30 PM CST
ALZHEIMER'S DISEASE
Revealing the Neuropathology of Alzheimer’s Disease Through Novel Fluid and Imaging Biomarkers: Ushering in a Precision Era of Diagnosis and Treatment
Val J. Lowe, MD
Mayo Clinic
Rochester, Minnesota
Jonathan E. McConathy, MD, PhD
University of Alabama at Birmingham
Heersink School of Medicine
Birmingham, Alabama
7:00 PM EST
DESMOID TUMORS
On the Cusp of Change: Modernizing the Treatment of Desmoid Tumors With Novel Gamma Secretase Inhibitors
Bernd Kasper, MD, PhD
University of Heidelberg
Mannheim Cancer Center (MCC)
Mannheim, Germany
7:00 AM PST
BLADDER CANCER
Personalizing Bladder Cancer Care in the Modern Therapeutic Era: One Size No Longer Fits All
Petros Grivas, MD, PhD
University of Washington
Fred Hutchinson Cancer Center
Seattle, Washington
Neal D. Shore, MD, FACS
Carolina Urologic Research Center
GenesisCare, US
Myrtle Beach, South Carolina
12:00 PM PST
PROSTATE CANCER
Case by Case: Maximizing Personalized Approaches to Prostate Cancer
Rana R. McKay, MD
UC San Diego Moores Cancer Center
University of California San Diego
La Jolla, California
Alicia K. Morgans, MD, MPH
Dana-Farber Cancer Center
Boston, Massachusetts
7:15 PM CST
BREAST CANCER
Clarifying the Complexities of the Expanding Treatment Options for Advanced- and Early-Stage HR+/HER2- Breast Cancer
Erika Hamilton, MD
Sarah Cannon Research
Institute/Tennessee Oncology
Nashville, Tennessee
11:30 AM PST
CHRONIC KIDNEY DISEASE
Novel Strategies for Managing Patients With CKD-Associated Anemia: What Do Health-System Pharmacists Need to Know About HIF-PH Inhibitors?
Jay B. Wish, MD
Indiana University Health
Indianapolis, Indiana
7:30 AM CST
LYMPHOMA
The Rising Tide of CAR-T in Lymphoma: Guidance on Leveraging Cellular Therapy to Improve Outcomes Across the Spectrum of Care
Jason Westin, MD, MS, FACP
The University of Texas
MD Anderson Cancer Center
Houston, Texas
7:30 AM CST
COLD AGGLUTININ DISEASE (CAD)
Demystifying Cold Agglutinin Disease: A Visual Exploration of Mechanism, Diagnosis, and the Role of Complement Inhibition in Addressing Unmet Needs
Sigbjørn Berentsen, MD, PhD
Haugesund Hospital
Haugesund, Norway
Ilene C. Weitz, MD
Keck-USC School of Medicine
Los Angeles, California
7:30 AM CST
CHRONIC LYMPHOCYTIC LEUKEMIA
The Winning Way With BTK Inhibitors in CLL: Evidence-Informed Choices on Treatment Selection, Safety, and Therapeutic Sequencing
John C. Byrd, MD
University of Cincinnati College of Medicine
Cincinnati, Ohio
7:30 AM CST
DIFFUSE LARGE B-CELL LYMPHOMA
Real-World, Real Innovation in DLBCL: Perspectives on Integrating Novel Antibody Platforms Into Patient Care
Grzegorz (Greg) Nowakowski, MD
Mayo Clinic
Rochester, Minnesota
7:30 AM CST
MULTIPLE MYELOMA
The Road to Remission in Multiple Myeloma: Expert Guidance on Using BCMA-Targeted Options to Enhance Clinical Outcomes
Nikhil C. Munshi, MD
Jerome Lipper Multiple Myeloma Center
Harvard Medical School
Boston, Massachusetts
7:30 AM CST
LEUKEMIA
The Sequel to the Targeted Therapy Era in CML: Guidance on Integrating Novel Options Into Cohesive Sequential Care
Vivian G. Oehler, MD
Fred Hutchinson Cancer Center
University of Washington
Seattle, Washington
7:30 AM CST
LYMPHOMA
Fixing the Target on Aggressive Lymphoma: Guidance on the Next Phase of Integrating Targeted Agents Into MCL and DLBCL Management
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD
Oxford University Hospitals
NHS Foundation Trust
Oxford, United Kingdom
7:30 AM CST
ACUTE MYELOID LEUKEMIA
Maintaining “Intensity” for Better Outcomes in AML: Guidance on Modern, Intensive Upfront Platforms in Challenging Patient Populations
Gail J. Roboz, MD
Weill Cornell Medical College
New York Presbyterian Hospital
New York, New York
11:00 AM CST
CHRONIC LYMPHOCYTIC LEUKEMIA
Fine-Tuning the Wave of Innovation in CLL: Personalized Models for Upfront and Sequential Care With Groundbreaking Treatment
Prof. John G. Gribben, MD, DSc
Barts Cancer Institute
Barts and The London School of Medicine, Queen Mary, University of London
London, England, United Kingdom
3:30 PM CST
MYELODYSPLASTIC SYNDROMES
The Future Is Now in MDS: Integrating Innovative, Risk-Adapted Therapies Into Patient Management
Guillermo Garcia-Manero, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas
1:00 PM EST
COVID-19
Improving Outcomes for Hospitalized Patients With COVID-19: Expert Perspectives on Incorporating the Latest Guidelines and Evidence Into Clinical Practice
Sanjay R. Bhagani, BSc (Hons), MB ChB, FRCP
Royal Free Hospital
London, England, United Kingdom
6:00 PM PST
GI MALIGNANCIES
Seek and You Will Find in Advanced GI Cancers: Identifying and Targeting Uncommon but Actionable Genomic Alterations
Vivek Subbiah, MD
The University of Texas MD Anderson Cancer Center
MD Anderson Cancer Center Network
Houston, Texas
6:00 PM PST
HCC
The HCC Revolution Continues: Exploring Evidence-Based Treatment Selection and Sequencing in Advanced Disease and Beyond
Ghassan Abou-Alfa, MD, MBA
Memorial Sloan Kettering Cancer Center
New York, New York
6:30 PM EST
CHRONIC LYMPHOCYTIC LEUKEMIA
Fine-Tuning the Wave of Innovation in CLL: Personalized Models for Upfront and Sequential Care With Groundbreaking Treatment
Nicole Lamanna, MD
Herbert Irving Comprehensive Cancer Center
New York-Presbyterian/Columbia University Medical Center
New York, New York
5:45 PM PST
BILIARY CANCER
Getting Personal With Advanced BTC: Insights on Personalizing Upfront and Sequential Care With Immunotherapy and Targeted Agents
Rachna T. Shroff, MD, MS
University of Arizona Cancer Center (UACC)
UA College of Medicine – Tucson (UA COM-T)
Tucson, Arizona
12:10 PM PST
NSCLC
Realizing the Promise of Perioperative Immunotherapy in Resectable NSCLC: How to Modernize Best Practices Based on New Evidence and Better Multidisciplinary Alliances
Nasser Altorki, MD
Weill Cornell Medicine
Meyer Cancer Center of Weill Cornell
New York, New York
Jonathan D. Spicer, MD, PhD, FRCSC
McGill University
Montreal General Hospital
Montreal, Quebec, Canada
12:40 PM PST
NSCLC
EGFR-Targeted Therapy for Early-Stage NSCLC: What Thoracic Surgeons Need to Know
Catherine Shu, MD
Columbia University Medical Center
New York, New York
7:00 PM EST
PSORIASIS
Understanding TYK2’s Role in Psoriasis Pathogenesis and Taking a Practical Approach to Realizing Its Potential in the Clinic
April W. Armstrong, MD, MPH
Keck School of Medicine
University of Southern California
Los Angeles, California
1:00 PM EST
COVID-19
Improving Outcomes for Hospitalized Patients With COVID-19: Expert Perspectives on Incorporating the Latest Guidelines and Evidence Into Clinical Practice
Sanjay R. Bhagani, BSc (Hons), MB ChB, FRCP
Royal Free Hospital
London, England, United Kingdom
7:00 PM EST
ALZHEIMER'S DISEASE
Gearing Up for Plasma Biomarkers in the Clinic: Real-World Strategies to Facilitate the Timely and Accurate Neuropathological Diagnosis of Alzheimer’s Disease
Marwan Sabbagh, MD, FAAN
Professor of Neurology, Alzheimer's and Memory Disorders Division
Barrow Neurological Institute
Research Professor
University of Arizona College of Medicine-Phoenix
Clinical Professor of Neurology
Creighton University
Phoenix, Arizona
7:00 PM EST
HCC
Essential Conversations for HCC: Radiology-Oncology Collaboration and Immunotherapy Advances in Intermediate and Advanced Disease
Riad Salem, MD, MBA
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Mark Yarchoan, MD
Sidney Kimmel Comprehensive Cancer Center
The Johns Hopkins University School of Medicine
Baltimore, Maryland
7:00 PM PST
RCC
Breaking New Ground in RCC Management: Expert Guidance on Leveraging Therapeutic Strategies
Sumanta Kumar Pal, MD, FASCO
City of Hope Comprehensive Cancer Center
Duarte, California
7:00 PM PST
BLADDER CANCER
Fresh Perspectives on Moving Toward Personalized Care for Bladder Cancer: Tips, Tools, and Strategies for Leveraging the Latest Advancements Across the Disease Spectrum
Matthew I. Milowsky, MD, FASCO
University of North Carolina at Chapel Hill
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina
6:30 PM PST
PROSTATE CANCER
Expanding Use of Hormonal Therapeutic Strategies in Prostate Cancer: Clinical Evidence and Practical Considerations for Individualized, Patient-Centered Care
Matthew R. Smith, MD, PhD
Harvard Medical School
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
6:30 PM PST
NSCLC
Refining Precision Decisions in NSCLC With Common and Less Common EGFR Mutations: Navigating Testing and Treatment Throughout the Disease Continuum
Natasha B. Leighl, MD, MMSc, FRCPC, FASCO
Princess Margaret Cancer Centre
PMC Foundation
University of Toronto
Dalla Lana School of Public Health
Toronto, Ontario, Canada
6:30 PM PST
NSCLC
Peer Pressure: How Well Do You Know Your ADCs? Answers to Key Questions About Antibody–Drug Conjugates in NSCLC
Benjamin Levy, MD
Johns Hopkins School of Medicine
Johns Hopkins Sidney Kimmel Cancer Center (SKCC) at Sibley Memorial Hospital
Washington, District of Columbia
6:45 AM CST
HYPERTROPHIC CARDIOMYOPATHY (HCM)
Loosening the Grip of Hypertrophic Cardiomyopathy: Updated Strategies for Timely Diagnosis and Disease-Modifying Treatment
Neal K. Lakdawala, MD
Brigham and Women’s Hospital
Harvard Medical School
Boston, Massachusetts
Anjali Tiku Owens, MD
University of Pennsylvania Perelman School of Medicine
Philadelphia, Pennsylvania
6:15 AM CDT
BREAST CANCER
A New View of the Spectrum of HER2 Expression and Significance of HER2 Low in Breast Cancer: Exploring the Biology and Updating Best Practices for Testing and Treatment
Stuart J. Schnitt, MD
Dana-Farber/Brigham and Women’s Cancer Center
Harvard Medical School
Boston, Massachusetts
Paolo Tarantino, MD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts
6:45 AM CDT
IMMUNO-ONCOLOGY BIOMARKERS
Gaining Confidence in Predicting and Assessing Response to Cancer Immunotherapies: Practical Strategies for Biomarker Testing and Pathologic Response Assessment
Lynette M. Sholl, MD
Brigham and Women’s Hospital
Harvard Medical School
Boston, Massachusetts
7:30 AM EST
CAR-T Therapy
Unlocking the Benefits of CAR-T Therapy in Hematologic Malignancies: Latest Evidence and Practical Considerations for Delivering State-of-the-Art Care
Caron Jacobson, MD
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts
11:30 AM EST
Chronic Lymphocytic Leukemia
Achieving Innovation in CLL Care: Evidence-Informed Choices With Targeted Options and Next Steps in Disease Management
John G. Gribben, MD, DSc, FRCP, FRCPath, FMedSci
Barts Cancer Institute
Barts and The London School of Medicine, Queen Mary, University of London
London, England, United Kingdom
7:15 PM MDT
Hypertrophic Cardiomyopathy
Easing the Burden of Hypertrophic Cardiomyopathy: Progress in Understanding and Addressing Its PathophysiologyAurora, Colorado
Daniel Jacoby, MD
Yale New Haven Health
Yale School of Medicine
New Haven, Connecticut
5:30 PM PDT
Eosinophilic Esophagitis
Fulfilling a Need in the Management of Patients With Eosinophilic Esophagitis: An Exploration of Novel and Emerging Therapeutic OptionsLas Vegas, NV
Evan S. Dellon, MD, MPH
UNC Center for Esophageal Diseases and Swallowing (CEDAS)
University of North Carolina School of Medicine
Chapel Hill, North Carolina
6:00 PM CDT
Pan Tumor
Implementing Synergistic Multimodal Approaches With Tumor Treating Fields to Extend Survival in Aggressive CancersChicago, IL
Erik P. Sulman, MD, PhD
NYU Grossman School of Medicine
Laura and Isaac Perlmutter Cancer Center
New York, New York
6:30 AM EDT
Immune-Related Adverse Events
Maintaining Vigilance to Mitigate Cancer Immunotherapy-Related Toxicities in the Emergency Department: Be Aware, Stay Alert, and Change Your PracticeBoston, MA
Mark M. Awad, MD, PhD
Lowe Center for Thoracic Oncology
Harvard Medical School
Boston, Massachusetts
6:30 AM EDT
Multiple Sclerosis
Exploring the Convergence of Advances in S1P Receptor Modulation With Progress in Understanding Brain Atrophy and Cognition Measures in Multiple SclerosisOrlando, Florida
Bruce Cree, MD, PhD, MAS
UCSF Weill Institute for Neurosciences
University of California San Francisco
San Francisco, California
6:30 PM EDT
Multiple Sclerosis
Bruton Tyrosine Kinase Inhibitors for MS: Progress in the Development of an Emerging Therapeutic ApproachOrlando, Florida
Benjamin M. Greenberg, MD, MHS
University of Texas Southwestern Medical Center
Dallas, Texas
Professor Anthony Traboulsee, MD
The MS Society
The University of British Columbia
Vancouver, British Columbia, Canada
12:15 PM EDT
NSCLC
Time for Even More Precision in Testing and Treatment of EGFR-Mutated NSCLC: Refining and Expanding Best Practices in Advanced and Early-Stage Disease SettingsBoston, MA
Lynette M. Sholl, MD
Brigham and Women’s Hospital
Harvard Medical School
Boston, Massachusetts
8:30 PM EDT
Renal Cell Carcinoma
Selecting and Sequencing Targeted and Immunotherapy Regimens for RCC: How Will the Latest Evidence Impact Treatment Decisions for My Patients?Austin, TX
Sumanta Kumar Pal, MD, FASCO
City of Hope Comprehensive Cancer Center
Duarte, California
12:15 PM EST
Glioblastoma
A New Wave of Progress in Glioblastoma: Expert Guidance on Delivering Modern Personalized Care With Tumor Treating Fields and Novel Systemic ApproachesBoston, MA
Steven Brem, MD
Penn Brain Tumor Center
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania
5:30 PM EST
Bladder Cancer
Breaking Down the Evidence in Bladder Cancer: Expert Perspectives and Practical Strategies on Immune, Targeted, and Antibody-Based TherapiesOrlando, FL
Petros Grivas, MD, PhD
University of Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington
6:30 AM EST
Prostate Cancer
Personalizing and Advancing Modern Treatment Approaches to Prostate CancerOrlando, FL
Robert Dreicer, MD, MS, MACP, FASCO
University of Virginia Cancer Center
Paul Mellon Urologic Cancer Institute
University of Virginia School of Medicine
Charlottesville, Virginia
Pedro C. Barata, MD, MSc
Tulane University Medical School
New Orleans, Louisiana
8:00 PM EST
Breast Cancer
Personalizing Treatment Decisions in HER2-Altered Breast Cancer: Strategies for Improving Equity and Patient Outcomes Through Individualized Targeted Therapy Selection, Team-Based Care, and Shared Decision-MakingSan Antonio, TX
Joyce O’Shaughnessy, MD
Baylor University Medical Center
Dallas, Texas
7:00 AM EST
Chronic Lymphocytic Leukemia
Customizing Care in CLL With BTK Inhibitors: Evidence and Applications for Therapy Selection, Sequencing, and Safety ManagementAtlanta, GA
John C. Byrd, MD
University of Cincinnati College of Medicine
Cincinnati, Ohio
7:00 AM EST
Diffuse Large B-Cell Lymphoma
Taking the Turn to Treatment Innovation in DLBCL: Real-World Insight on Integrating Antibodies and Cellular Therapy Into Patient CareAtlanta, GA
Grzegorz (Greg) Nowakowski, MD
Mayo Clinic
Rochester, Minnesota
7:00 AM EST
CAR-T Therapy
Unlocking the Benefits of CAR-T Therapy in Hematologic Malignancies: Latest Evidence and Practical Considerations for Delivering State-of-the-Art CareAtlanta, GA
Caron Jacobson, MD
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts
7:00 AM EST
Acute Myeloid Leukemia
Seizing Opportunity in AML: How to Realize the Potential of Novel Therapeutics in Diverse Patient PopulationsAtlanta, GA
Naval Daver, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas
7:00 AM EST
Multiple Myeloma
A Is for Antibody in Multiple Myeloma: Practical Insights and Patient Voices Along the Therapeutic JourneyAtlanta, GA
Suzanne Lentzsch, MD, PhD
Columbia University Medical Center
New York, New York
7:00 AM EST
Sickle Cell Disease
The Evolution of Sickle Cell Disease: Current Advances and Future PossibilitiesAtlanta, GA
Biree Andemariam, MD
University of Connecticut Health
Farmington, Connecticut
11:00 AM EST
Chronic Lymphocytic Leukemia
Achieving Innovation in CLL Care: Evidence-Informed Choices With Targeted Options and Next Steps in Disease ManagementAtlanta, GA
John G. Gribben, MD, DSc, FRCP, FRCPath, FMedSci
Barts Cancer Institute
Barts and The London School of Medicine, Queen Mary, University of London
London, England, United Kingdom
6:00 PM PST
Hepatocellular Carcinoma
Mapping the Optimal Treatment Route in HCC: Identifying Best Practices in an Expanding Therapeutic LandscapeSan Francisco, CA
Richard S. Finn, MD
David Geffen School of Medicine at UCLA
Los Angeles, California
6:00 PM PST
Biliary Cancers
Embracing the Era of Individualized Therapy in Advanced Biliary Cancers: Expert Strategies for Applying New and Emerging Targeted Treatment Options Through Precision MedicineSan Francisco, CA
Milind Javle, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas
6:30 PM CST
Stroke
Mastering the Use of Dual Antiplatelet Therapy for Preventing Recurrent Stroke: How Well Do Your Current Strategies Match With the Experts?New Orleans, LA
Gregory W. Albers, MD
Stanford University
Stanford Stroke Center
Stanford, California
S. Claiborne “Clay” Johnston, MD, PhD
Dell Medical School
The University of Texas at Austin
Austin, Texas
6:45 PM PST
Renal Cell Carcinoma
Navigating Evolving Standards of Care in Renal Cell Carcinoma: Expert Insights on Selecting and Sequencing Targeted and Immunotherapy Options and a Look at Emerging StrategiesSan Francisco, CA
Sumanta Kumar Pal, MD, FASCO
City of Hope Comprehensive Cancer Center
Duarte, California
6:45 PM PST
Bladder Cancer
Achieving State-of-the-Art Care in Bladder Cancer in an Era of Innovative Therapeutic SolutionsSan Francisco, CA
Petros Grivas, MD, PhD
University of Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington
6:15 PM PST
Prostate Cancer
Decisions and Dilemmas in Prostate Cancer Management: Building on Progress to Advance Personalized Care Through Candid Conversations and Expert Clinical ConsultsSan Francisco, CA
Robert Dreicer, MD, MS, MACP, FASCO
University of Virginia Comprehensive Cancer Center
Paul Mellon Urologic Cancer Institute
University of Virginia School of Medicine
Charlottesville, Virginia
6:30 PM EST
Multiple Sclerosis
Rationale, Evidence, and Practical Potential for BTK Inhibitors in Patient-Centered MS Care: Where We Stand NowWest Palm Beach, FL
Amit Bar-Or, MD, FRCPC
Center for Neuroinflammation and Experimental Therapeutics
Perelman Center for Advanced Medicine (PCAM)
University of Pennsylvania
Philadelphia, Pennsylvania
Daniel S. Reich, MD, PhD
National Institute of Neurological Disorders and Stroke
National Institutes of Health*
Bethesda, Maryland
*Participation in this CME event as an "outside activity"
6:30 AM MST
Severe Asthma
Taking It From the Top: Targeting a New Approach to Controlling Severe AsthmaPhoenix, AZ
Purvi S. Parikh, MD, FACP, FACAAI
New York University School of Medicine
New York, New York
Cedric "Jamie" Rutland, MD
American Lung Association
Rutland Medical Group
UCR School of Medicine
Newport Beach, California
6:45 PM CST
Melanoma
Linking Immunotherapy to Better Outcomes in Resectable Melanoma: Guidance on Integrating Immune-Based Adjuvant and Neoadjuvant OptionsDallas, TX
Jennifer Wargo, MD, MMSc
The University of Texas MD Anderson Cancer Center
Houston, Texas
4:45 PM CST
Breast Cancer
Translating Progress With Immunotherapies and Targeted Agents Into Improved Outcomes in Triple-Negative Breast Cancer: Surgical and Clinical Perspectives on Modern Multimodal Treatment ApproachesDallas, TX
Henry M. Kuerer, MD, PhD, FACS
The University of Texas MD Anderson Cancer Center
Houston, Texas
Heather L. McArthur, MD, MPH
UT Southwestern Medical Center
Dallas, Texas
5:00 PM CET
Alzheimer’s Disease
Accelerating Progress in the Treatment of Alzheimer’s Disease: How Can We Achieve Timely and Accurate Neuropathological Diagnosis and Precision Management of Mild Cognitive Impairment in Early Alzheimer’s Disease?Barcelona, Spain
Liana G. Apostolova, MS, MD, FAAN
Indiana University School of Medicine
Indiana Alzheimer's Disease Center
Indianapolis, Indiana
6:00 AM PDT
Immuno-Oncology Biomarkers
Progress and Practicalities in Immunotherapy Biomarker Testing and Pathologic Response Assessment in Solid Tumors: What’s New and What You Need to Know and DoLos Angeles, CA
Kurt A. Schalper, MD, PhD
Yale School of Medicine
Yale Cancer Center
New Haven, Connecticut
6:00 AM PDT
HER2/HER3/TROP2 Testing/Treatment
Decoding the Latest Evidence and Practical Recommendations on Biomarker Testing for New Therapeutic Options Targeting HER2, HER3, and TROP2 in Solid TumorsLos Angeles, CA
Kurt A. Schalper, MD, PhD
Yale School of Medicine
Yale Cancer Center
New Haven, Connecticut
6:30 PM EDT
Prurigo Nodularis
Addressing the Burden of Prurigo Nodularis: Expert Insight on Disease Pathogenesis and the Clinical Potential of Novel Therapeutic OptionsBoston, MA
Sarina Elmariah, MD, PhD, MPH
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts
Shawn Kwatra, MD
Johns Hopkins University School of Medicine
Baltimore, Maryland
6:30 PM EDT
Chronic Spontaneous Urticaria
Advances in Chronic Spontaneous Urticaria: Expert Insight on Translating Progress to Practice for Improved Symptom Control and Quality of LifeBoston, MA
Joseph Diaz, MD
Allergy, Asthma, & Immunology Associates of South Texas
San Antonio, Texas
Erika Gonzalez, MD
South Texas Allergy & Asthma Medical Professionals
University of Texas Health Science Center
San Antonio, Texas
6:15 AM PDT
PARP Inhibitors
Expanding the Benefits of PARP Inhibitor Therapy to More Patients With Breast Cancer and Earlier Disease Settings: Multidisciplinary Perspectives on How to Maximize the Potential of PARP Inhibitors and Optimize Their Use as Part of Multimodal Management of Breast CancerLas Vegas, NV
Henry M. Kuerer, MD, PhD, FACS
The University of Texas MD Anderson Cancer Center
Houston, Texas
6:30 PM CDT
Cancer Immunotherapy
Parsing the Practicalities of Pathologic Response Assessment After Neoadjuvant Immunotherapy to Facilitate Progress in Early-Stage CancersNew Orleans
Prof. Solange Peters, MD, PhD
University Hospital of Lausanne
Lausanne, Switzerland
12:00 PM MST
Graft-Versus-Host Disease
Overcoming the Challenges of Acute and Chronic GVHD: The Integration of Novel Therapies Into Modern Management ProtocolsSalt Lake City, UT
Leslie Kean, MD, PhD
Harvard Medical School
Boston Children's Hospital
Dana-Farber Cancer Institute
Boston, Massachusetts
6:30 AM MDT
Acute Myeloid Leukemia
Landmarks Across the Patient Journey in AML: Applying Evidence With Novel Therapeutics Pre- and Post-AlloHCTSalt Lake City, UT
James M. Foran, MD, FRCPC
Mayo Clinic Cancer Center
Jacksonville, Florida
7:00 AM MDT
Leukemia
CAR-T Cell Therapy: Are You Up to the Challenge? New Evidence and Best Practices Driving Modern Cellular Therapies as a Standard of Care for Leukemia and LymphomaSalt Lake City, UT
Michael R. Bishop, MD
The David and Etta Jonas Center for Cellular Therapy
University of Chicago
Chicago, Illinois
6:30 AM MDT
Myelofibrosis
The Modern Management of Myelofibrosis: Practical Perspectives Surrounding the Use of JAK Inhibitors and Novel Therapeutics in the Peri-Transplant SettingSalt Lake City, UT
Jeanne M. Palmer, MD
Mayo Clinic
Phoenix, Arizona
Srdan Verstovsek, MD, PhD
The University of Texas MD Anderson Cancer Center
Houston, Texas
6:30 AM MST
Chronic Lymphocytic Leukemia
Reaping the Rewards of Innovative Care in CLL: From Targeted Standards to Cellular TherapySalt Lake City, UT
John N. Allan, MD
Weill Cornell Medicine
New York, New York
Alexey V. Danilov, MD, PhD
Toni Stephenson Lymphoma Center
City of Hope National Medical Center
Duarte, California
11:30 AM MDT
Veno-Occlusive Disease
Upgrading the VOD/SOS Management Tool Kit: Guidance for Effective Diagnostic Confirmation, Grading, and TreatmentSalt Lake City, UT
Nelson Chao, MD, MBA
Duke Cancer Institute/Duke Global Health Institute
Durham, North Carolina
Christine N. Duncan, MD
Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Boston Children’s Hospital
Harvard Medical School
Boston, Massachusetts
11:45 AM PDT
Solid Tumors
Tackling the Practicalities of Antibody–Drug Conjugate Therapy for Solid Tumors: Improving Clinical Care With HER2-, HER3-, and TROP2-Targeted TherapiesAnaheim, CA
Linda Ahn, MSN, ANP-BC, AOCNP
Memorial Sloan Kettering Cancer Center
New York, New York
5:30 AM PDT
Chronic Lymphocytic Leukemia
Hope Is Here in CLL: Oncology Nurse Strategies for Delivering Effective, Compassionate, and Modern Care to PatientsAnaheim, CA
Amy Goodrich, CRNP
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland
5:30 PM PDT
Renal Cell Carcinoma
Aligning Nursing Care Strategies With Evolving Patient Needs in RCC: Interprofessional Insights on Optimizing Outcomes With Novel Targeted and Immune-Based TherapiesAnaheim, CA
Nancy P. Moldawer, RN, MSN
Cedars-Sinai Medical Center
Los Angeles, California
7:00 AM EDT
Neurofibromatosis
Revolutionizing the Standard of NF1 Care: Insights on Innovative MEK-Inhibitor Options for NF1-Associated PNsPittsburgh, PA
Bruce R. Korf, MD, PhD
UAB School of Medicine
University of Alabama at Birmingham
Birmingham, Alabama
Miriam Bornhorst, MD
Children’s National Hospital
Washington, DC
12:15 PM EDT
Acute Lymphoblastic Leukemia
Adapting to Innovation in Pediatric ALL: Guidance on Optimizing Modern Therapy and the Role of Novel Asparaginase CompoundsPittsburgh, PA
Stuart S. Winter, MD
Children's Minnesota
Minneapolis, Minnesota
Reuven Schore, MD
Children’s National Hospital
The George Washington University School of Medicine and Health Sciences
Washington, District of Columbia
5:30 PM CDT
Bladder Cancer
Urology Clinical Consults: Bladder Cancer Cases From the Community—Expert Guidance on Translating the Latest Therapeutic Advances Into Patient Care for Early to Advanced Bladder CancerNew Orleans, LA
Ashish M. Kamat, MD, MBBS
The University of Texas MD Anderson Cancer Center
Houston, Texas
12:00 PM EDT
NSCLC
How to Integrate Perioperative Immunotherapy Into Multimodal Treatment Plans to Improve Outcomes in Resectable NSCLCBoston, MA
Nasser Altorki, MD
Weill Cornell Medicine
Meyer Cancer Center of Weill Cornell
New York, New York
Jonathan D. Spicer, MD, PhD, FRCSC
McGill University
Montreal General Hospital
Montreal, Quebec, Canada
6:30 AM EDT
Multiple Sclerosis
Innovations and Imaging in Multiple Sclerosis: Examining the Evidence, Looking Toward the Future of Bruton Tyrosine Kinase InhibitorsNational Harbor, MD
Benjamin M. Greenberg, MD, MHS
University of Texas Southwestern Medical Center
Dallas, Texas
Professor Anthony Traboulsee, MD
The MS Society
The University of British Columbia
Vancouver, British Columbia, Canada
6:30 PM CDT
Chronic Lymphocytic Leukemia
Rewriting the Treatment Script in CLL: Guidance on Integrating Modern Targeted and Next-Gen Options Into Patient CareChicago, Illinois
Anthony R. Mato, MD, MSCE
Memorial Sloan Kettering Cancer Center
New York, New York
6:30 AM EDT
Multiple Sclerosis
Re-Examining S1PR Modulation From All Angles in Relapsing Multiple Sclerosis: Impact on Physical and Cognitive Outcomes, and Practical Considerations of Long-Term TherapyNational Harbor, MD
Bruce Cree, MD, PhD, MAS
UCSF Weill Institute for Neurosciences
University of California San Francisco
San Francisco, California
6:30 PM CDT
Melanoma
New Rules for Sequential Care in BRAF-Mutated Melanoma: Rethinking Upfront Selection and Sequencing of Immunotherapy and Targeted Agents in Metastatic DiseaseChicago, Illinois
Hussein A. Tawbi, MD, PhD
The University of Texas
MD Anderson Cancer Center
Houston, Texas
6:30 PM CDT
AML
The Advantage of Innovation in AML: Guidance on Developing and Delivering Effective and Highly Personalized CareChicago, IL
Gail J. Roboz, MD
Weill Cornell Medical College
New York Presbyterian Hospital
New York, New York
6:30 PM CDT
Small Cell Lung Cancer
Assessing the Impact of Therapeutic Advances in SCLC: Instilling New Hope and Moving in Leaps and Bounds Toward Better OutcomesChicago, IL
Jacob Sands, MD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts
6:30 PM CDT
RCC
Refining RCC Management Across the Disease Continuum: An Expert Clinical Consult on Leveraging New Evidence and Novel Therapeutic Strategies to Personalize Patient CareChicago, IL
Toni K. Choueiri, MD
Lank Center for Genitourinary Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts
5:30 AM CDT
DR/DME
A Call to Action for Diabetes Specialists: Your Role in Saving the Eyesight of Patients With DiabetesNew Orleans, Louisiana
Richard Beaser, MD
Joslin Diabetes Center
Harvard Medical School
Boston, Massachusetts
12:30 PM EDT
COVID-19
Do You Know How to Use COVID-19 Monoclonal Antibodies as Pre-Exposure Prophylaxis for Your Post-Transplant Patients? Test Your KnowledgeBoston, MA
Shmuel Shoham, MD
Professor of Medicine
Transplant and Oncology Infectious Diseases Program
Division of Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, Maryland
Myron S. Cohen, MD
Yeargan-Bate Eminent Professor of Medicine, Microbiology and Epidemiology
Associate Vice Chancellor for Medical Affairs and Global Health
Director, Institute for Global Health and Infectious Diseases
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
6:30 PM CDT
CAR-T THERAPY
Rising to the Occasion: Improving Outcomes in Leukemia, Lymphoma, and Multiple Myeloma With CAR-T Therapy in Community PracticeChicago, IL
Jason Westin, MD, MS, FACP
The University of Texas MD Anderson Cancer Center
Houston, Texas
6:30 PM CDT
HCC/LIVER CANCER
Setting the Course for the Optimal Management of HCC: Improving Patient Outcomes Through the Integration of Novel Therapeutic Approaches Across the Continuum of CareChicago, IL
Richard S. Finn, MD
Professor of Clinical Medicine
Division of Hematology/Oncology
David Geffen School of Medicine at UCLA
Los Angeles, California
6:30 PM CDT
NSCLC
Find the Targets, Treat With Precision: Modern Principles and New Advances in Biomarker-Driven Lung Cancer CareChicago, IL
Stephen V. Liu, MD
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC
6:30 PM CDT
MULTIPLE MYELOMA
The “Myelennial” Generation: Managing the Boom of Innovative Therapy to Transform Myeloma Care and Enhance Patient OutcomesChicago, IL
Nina Shah, MD
UCSF Helen Diller Family Comprehensive Cancer Center
The University of California, San Francisco
San Francisco, California
6:30 PM CDT
HEAD AND NECK CANCER
The Power and Promise of Immunotherapy in Head and Neck Cancer: How Established and Emerging Immune-Based Options Can Enhance Patient CareChicago, IL
Robert I. Haddad, MD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts
6:30 PM CDT
NSCLC
Gaining an Advantage Over NSCLC: How to Achieve the Greatest Benefit With Immunotherapy From Advanced to Early DiseaseChicago, IL
David P. Carbone, MD, PhD
International Association for the Study of Lung Cancer
James Thoracic Oncology Center
James Cancer Center
The Ohio State University Medical Center
Columbus, Ohio
6:30 PM CDT
MELANOMA
Choosing Innovation With Immunotherapy in Melanoma: Guidance on Utilizing Immune-Based and Other Novel Options in Resectable and Unresectable DiseaseChicago, IL
Michael B. Atkins, MD
Georgetown-Lombardi Comprehensive Cancer Center
Georgetown University School of Medicine
Washington, District of Columbia
6:30 PM CDT
BASAL CELL CARCINOMA
Immunotherapy Has Arrived in Advanced BCC: Collaborative Strategies for Making the Most of Novel Immune-Based TreatmentChicago, IL
Karl D. Lewis, MD
University of Colorado Anschutz Medical Campus
University of Colorado Cancer Center
Aurora, Colorado
6:30 PM CDT
BLADDER CANCER
Blazing the Trail Forward in the Therapeutic Management of Bladder Cancer: Expert Insights on Incorporating the Latest Evidence and Treatment Advancements Into Practice Across the Disease ContinuumChicago, IL
Petros Grivas, MD, PhD
University of Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington
6:30 PM CDT
METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
Realizing the Potential of Novel Treatment Intensification Strategies for Metastatic Castration-Sensitive Prostate Cancer: The Experts’ Take on Key Clinical Evidence, Practical Considerations, and Best Practices for Individualized, Patient-Centered CareChicago, IL
Matthew R. Smith, MD, PhD
Harvard Medical School
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
07:45 CEST
B-Cell Cancers
Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies: New Evidence on the Individualized Use of BTK Inhibitors in Relapsed/Refractory CLL/SLL and MCLWien, Austria
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD
Oxford University Hospitals
NHS Foundation Trust
Oxford, United Kingdom
Anthony R. Mato, MD, MSCE
Memorial Sloan Kettering Cancer Center
New York, New York
10:00 CEST
Chronic Lymphocytic Leukemia
New Rules for BTK Inhibitors in CLL: Benchmarks for Evidence-Based Treatment Selection, Sequencing, and Safety ManagementWien, Austria
Prof. Dr. med. Stephan Stilgenbauer
Comprehensive Cancer Center Ulm
Ulm University
Ulm, Germany
17:45 CEST
ACUTE LYMPHOBLASTIC LEUKEMIA
The Path for Better Outcomes in ALL: Integrating Modern Asparaginase Compounds Into the Care of Pediatric, AYA, and Adult PatientsWien, Austria
Prof. Carmelo Rizzari
President of the European Society of Pediatric Oncology (SIOPE)
Professor of Pediatrics
University of Milano-Bicocca
Head, Pediatric Hematology Oncology Unit
MBBM Foundation, ASST Monza
Monza, Italy
11:45 AM EDT
HCC/LIVER CANCER
Making Headway Towards Better Outcomes in Intermediate- to Advanced-Stage Hepatocellular Carcinoma: A Multidisciplinary Tumor Board on Implementing Novel Locoregional and Systemic ApproachesSouth Boston, MA
Riad Salem, MD, MBA
Northwestern University Feinberg School of Medicine
Chicago, Illinois
13:25 CEST
Gastric Cancer
Realizing Improved Outcomes in HER2-Positive Gastrointestinal Cancers: New Evidence and Practical Guidance With Targeted AgentsBarcelona, Spain
Elena Elez, MD, PhD
Vall d’Hebron Institute of Oncology
Barcelona, Spain
Yelena Y. Janjigian, MD
Memorial Sloan Kettering Cancer Center
New York, New York
7:00 AM PDT
Prurigo Nodularis
Taking a New Look at Prurigo Nodularis: How Is Emerging Evidence Regarding Disease Pathophysiology and Treatment Influencing Patient Care?Vancouver, BC
Sarah S. Chisolm, MD
Emory University
VISN 7, VA
Atlanta, Georgia
Brian S. Kim, MD, MTR
Friedman Brain Institute
Icahn School of Medicine at Mount Sinai
New York, New York
10:00 CEST
Breast Cancer
Targeting HER2-Low Expression in Breast Cancer: Evaluating the Evidence, Challenges, and Opportunities for Expanding Treatment Benefit to More PatientsParis, France
Professor Aleix Prat, MD, PhD
Hospital Clínic Barcelona
University of Barcelona
Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)
Barcelona, Spain
18:00 CEST
Breast Cancer
SERDs at the Inflection Point in Pretreated ER+/HER2- Breast Cancer: Addressing Unmet Needs, Establishing New Standards of Care, and Improving Patient Outcomes With Novel ER-Targeting TherapiesParis, France
Javier Cortes, MD, PhD
International Breast Cancer Center (IBCC)
Barcelona, Spain
7:00 PM CDT
NSCLC
Are You Prepared for the New Wave of ADCs in NSCLC? Innovative Approaches and Practical Considerations in Targeting HER2, HER3, TROP2, and Other Alterations in Advanced Lung CancerChicago, IL
Marina Chiara Garassino, MD
University of Chicago Medicine
Chicago, Illinois
6:30 AM CDT
NSCLC
Refining Biomarker Testing and Targeted Treatment of NSCLC With Common and Uncommon EGFR MutationsChicago, IL
Natasha B. Leighl, MD, MMSc, FRCPC, FASCO
Princess Margaret Cancer Centre
PMC Foundation
University of Toronto
Dalla Lana School of Public Health
Toronto, Ontario, Canada
12:41 PM CDT
ACUTE MYELOID LEUKEMIA
The Power of Personalized Medicine in AML: Linking Individualized Treatment to Enhanced Patient OutcomesHouston, TX
Naval Daver, MD
The University of Texas
MD Anderson Cancer Center
Houston, Texas
Amir T. Fathi, MD
Massachusetts General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts
12:41 PM CDT
CHRONIC LYMPHOCYTIC LEUKEMIA
Challenges and Changes With Targeted Options in CLL: Guidance on Making Evidence-Informed Upfront and Sequential Treatment ChoicesHouston, TX
Nicole Lamanna, MD
Herbert Irving Comprehensive Cancer Center
New York-Presbyterian/Columbia University Medical Center
New York, New York
Deborah M. Stephens, DO
University of Utah/Huntsman Cancer Institute
Salt Lake City, Utah
11:50 AM CDT
MULTIPLE MYELOMA
Progress on the Path to Better Outcomes in RRMM: Expert Perspectives on the Further Integration of BCMA-Directed Antibodies and Cellular TherapiesHouston, TX
Sagar Lonial, MD, FACP
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia
Krina Patel, MD, MSc
The University of Texas
MD Anderson Cancer Center
Houston, Texas
12:15 PM EDT
NSCLC
Precision Decisions in Multimodal Management of Early-Stage NSCLC: Integrating EGFR-Targeted Therapy in Perioperative SettingsNew York, NY
Brendon M. Stiles, MD
Montefiore-Einstein Cancer Center
Albert Einstein College of Medicine
Montefiore Medical Center
New York, New York
6:30 PM EDT
NSCLC
Extending Survival and Setting Our Sights on Cure in Resectable NSCLC: Getting the Details of Perioperative Immunotherapy RightNew York, NY
Nasser Altorki, MD
Weill Cornell Medicine
Meyer Cancer Center of Weill Cornell
New York, New York
Jonathan D. Spicer, MD, PhD, FRCSC
McGill University
Montreal General Hospital
Montreal, Quebec, Canada
6:30 PM CDT
MULTIPLE MYELOMA
The Eye-Deal Connection in Multiple Myeloma: Establishing Ophthalmology-Oncology Relationships to Overcome Ocular ToxicityChicago, IL
Praneetha Thulasi, MD
Emory Eye Center
Emory University School of Medicine
Atlanta, Georgia
Jonathan L. Kaufman, MD
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia
5:30 PM EDT
GENERALIZED MYASTHENIA GRAVIS
A Targeted Approach to Management of Generalized Myasthenia Gravis: The Latest on Novel Therapies That Improve Patient OutcomesNational Harbor, MD
James F. Howard Jr., MD
The University of North Carolina
Chapel Hill, North Carolina
6:30 AM EDT
Hypertrophic Cardiomyopathy
Pushing Back Against HCM: Can Cardiac Myosin Inhibitors Alter the Disease Progression and Management Trajectory for Patients With Hypertrophic Cardiomyopathy?National Harbor, MD
Milind Desai, MD, MBA
Cleveland Clinic Lerner College of Medicine
HCM Center
Heart and Vascular Institute
Cleveland, Ohio
6:00 PM EDT
EOSINOPHILIC ESOPHAGITIS
Updates in Eosinophilic Esophagitis: Exploring Underlying Mechanisms and Integrating Novel Targeted Therapy to Improve Patient CareOrlando, FL
Sandeep K. Gupta, MD
Community Health Network
Riley Hospital for Children
Indiana University School of Medicine
Indianapolis, Indiana
6:15 AM CDT
ASTHMA
Selecting Targeted Treatment for Pediatric and Adult Patients With Uncontrolled Moderate to Severe AsthmaNashville, TN
Leonard B. Bacharier, MD
Monroe Carell Jr. Children’s Hospital at Vanderbilt University Medical Center
Nashville, Tennessee
Monica Kraft, MD
Icahn School of Medicine at Mount Sinai
Mount Sinai Health System
New York, New York
6:00 PM CDT
SOLID TUMORS
Harnessing Novel Synergies With Tumor Treating Fields: Insights on Improving Survival With Multimodal Care in Aggressive TumorsSan Antonio, TX
Erik P. Sulman, MD, PhD
NYU Grossman School of Medicine
Laura and Isaac Perlmutter Cancer Center
New York, New York
6:30 PM CDT
RENAL CELL CARCINOMA
RCC Clinical Consults: Making Difficult Treatment Decisions at the Intersection of the Data and the Real WorldAustin, Texas
Sumanta Kumar Pal, MD, FASCO
City of Hope Comprehensive Cancer Center
Duarte, California
6:00 AM CDT
CARDIAC IRAES
Updating Our Cardio-Oncology Skills in the Cancer Immunotherapy Era: Team-Based Strategies for Risk Assessment, Diagnosis, and Management of Myocarditis and Other Cardiac Immune-Related Adverse EventsChicago, IL
Javid Moslehi, MD
UCSF School of Medicine
Cardiovascular Research Institute (CVRI)
San Francisco, California
1:00 PM EDT
HCC/LIVER CANCER
It Takes a Team for HCC: Improving Outcomes Through Multidisciplinary Collaboration & Modern TherapeuticsWashington, DC
Amit Singal, MD, MS
UT Southwestern Medical Center
Dallas, Texas
5:30 PM CDT
HEART FAILURE
How I Think, How I Treat: Cardiology-Focused Perspectives on Using SGLT2 Inhibitors to Optimize Outcomes in Patients With Heart FailureChicago, IL
Javed Butler, MD, MPH, MBA
Baylor Scott and White Research Institute
Dallas, Texas
University of Mississippi
Jackson, Mississippi
6:00 AM CST
HYPERLIPIDEMIA
Personalizing the Management of Hyperlipidemia: Addressing Unmet Needs Among High-Risk Patients With Atherosclerotic Cardiovascular Disease With Novel Lipid-Lowering TherapiesChicago, IL
Peter H. Jones, MD, MNLA
Center for Cardiometabolic Disease Prevention
Houston Methodist DeBakey Heart and Vascular Center
Baylor College of Medicine
Houston, Texas
R. Scott Wright, MD
Mayo Clinic
Rochester, Minnesota
8:00 PM EST
SEVERE ASTHMA
Leveling the Playing Field for All Patients With Severe Asthma: Directing New Treatment Approaches at the Airway EpitheliumLouisville, KY
Juan Carlos Cardet, MD
University of South Florida
Tampa, Florida
Geoffrey L. Chupp, MD
Yale School of Medicine
Yale Center for Asthma and Airway Disease
Yale New Haven Hospital
New Haven, Connecticut
7:30 AM EST
LUPUS
How I Think, How I Treat—Assessing, Managing, and Engaging Patients to Optimize Care in SLE and LN: Comparing Approaches With the ExpertsPhiladelphia, PA
Maureen A. McMahon, MD
UCLA David Geffen School of Medicine
Los Angeles, California
12:15 CET
BREAST CANCER
TROP2-Targeting ADCs as New Tools in the TNBC and HR+/HER2- Breast Cancer Treatment Arsenal: Advancing Patient-Centered Care to Make the Most of Modern Targeted TreatmentsBarcelona, Spain
Professor Peter Schmid, FRCP, MD, PhD
Centre for Experimental Cancer Medicine
Bart's Cancer Institute, Queen Mary University of London
London, England, United Kingdom
5:15 PM EST
GLIOBLASTOMA
Setting Our Sights on Improved Outcomes in Glioblastoma: State-of-the-Art Care With Tumor Treating Fields and Other Innovative ApproachesTampa, FL
Steven Brem, MD
Penn Brain Tumor Center
Perelman School of Medicine
Abramson Cancer Center, University of Pennsylvania
Philadelphia, Pennsylvania
7:00 PM PST
DESMOID TUMORS
On the Cusp of Change: Modernizing the Treatment of Desmoid Tumors With Novel Gamma Secretase InhibitorsVancouver, BC
Bernd Kasper, MD, PhD
University of Heidelberg
Mannheim Cancer Center (MCC)
Mannheim, Germany
1:30 PM CST
ALZHEIMER'S DISEASE
Revealing the Neuropathology of Alzheimer’s Disease Through Novel Fluid and Imaging Biomarkers: Ushering in a Precision Era of Diagnosis and TreatmentChicago, Illinois
Val J. Lowe, MD
Mayo Clinic
Rochester, Minnesota
Jonathan E. McConathy, MD, PhD
University of Alabama at Birmingham
Heersink School of Medicine
Birmingham, Alabama
6:30 AM PST
BLADDER CANCER
Personalizing Bladder Cancer Care in the Modern Therapeutic Era: One Size No Longer Fits AllSan Diego, CA
Petros Grivas, MD, PhD
University of Washington
Fred Hutchinson Cancer Center
Seattle, Washington
Neal D. Shore, MD, FACS
Carolina Urologic Research Center
GenesisCare, US
Myrtle Beach, South Carolina
11:30 AM PST
PROSTATE CANCER
Case by Case: Maximizing Personalized Approaches to Prostate CancerSan Diego, CA
Rana R. McKay, MD
UC San Diego Moores Cancer Center
University of California San Diego
La Jolla, California
Alicia K. Morgans, MD, MPH
Dana-Farber Cancer Center
Boston, Massachusetts
7:00 PM CST
BREAST CANCER
Clarifying the Complexities of the Expanding Treatment Options for Advanced- and Early-Stage HR+/HER2- Breast CancerSan Antonio, TX
Erika Hamilton, MD
Sarah Cannon Research
Institute/Tennessee Oncology
Nashville, Tennessee
10:45 AM PST
CHRONIC KIDNEY DISEASE
Novel Strategies for Managing Patients With CKD-Associated Anemia: What Do Health-System Pharmacists Need to Know About HIF-PH Inhibitors?Las Vegas, NV
Jay B. Wish, MD
Indiana University Health
Indianapolis, Indiana
7:00 AM CST
LYMPHOMA
The Rising Tide of CAR-T in Lymphoma: Guidance on Leveraging Cellular Therapy to Improve Outcomes Across the Spectrum of CareNew Orleans, LA
Jason Westin, MD, MS, FACP
The University of Texas
MD Anderson Cancer Center
Houston, Texas
7:00 AM CST
COLD AGGLUTININ DISEASE (CAD)
Demystifying Cold Agglutinin Disease: A Visual Exploration of Mechanism, Diagnosis, and the Role of Complement Inhibition in Addressing Unmet NeedsNew Orleans, LA
Sigbjørn Berentsen, MD, PhD
Haugesund Hospital
Haugesund, Norway
Ilene C. Weitz, MD
Keck-USC School of Medicine
Los Angeles, California
7:00 AM CST
CHRONIC LYMPHOCYTIC LEUKEMIA
The Winning Way With BTK Inhibitors in CLL: Evidence-Informed Choices on Treatment Selection, Safety, and Therapeutic SequencingNew Orleans, LA
John C. Byrd, MD
University of Cincinnati College of Medicine
Cincinnati, Ohio
7:00 AM CST
DIFFUSE LARGE B-CELL LYMPHOMA
Real-World, Real Innovation in DLBCL: Perspectives on Integrating Novel Antibody Platforms Into Patient CareNew Orleans, LA
Grzegorz (Greg) Nowakowski, MD
Mayo Clinic
Rochester, Minnesota
7:00 AM CST
MULTIPLE MYELOMA
The Road to Remission in Multiple Myeloma: Expert Guidance on Using BCMA-Targeted Options to Enhance Clinical OutcomesNew Orleans, LA
Nikhil C. Munshi, MD
Jerome Lipper Multiple Myeloma Center
Harvard Medical School
Boston, Massachusetts
7:00 AM CST
LEUKEMIA
The Sequel to the Targeted Therapy Era in CML: Guidance on Integrating Novel Options Into Cohesive Sequential CareNew Orleans, LA
Vivian G. Oehler, MD
Fred Hutchinson Cancer Center
University of Washington
Seattle, Washington
7:00 AM CST
LYMPHOMA
Fixing the Target on Aggressive Lymphoma: Guidance on the Next Phase of Integrating Targeted Agents Into MCL and DLBCL ManagementNew Orleans, LA
Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD
Oxford University Hospitals
NHS Foundation Trust
Oxford, United Kingdom
7:00 AM CST
ACUTE MYELOID LEUKEMIA
Maintaining “Intensity” for Better Outcomes in AML: Guidance on Modern, Intensive Upfront Platforms in Challenging Patient PopulationsNew Orleans, LA
Gail J. Roboz, MD
Weill Cornell Medical College
New York Presbyterian Hospital
New York, New York
11:00 AM CST
CHRONIC LYMPHOCYTIC LEUKEMIA
Fine-Tuning the Wave of Innovation in CLL: Personalized Models for Upfront and Sequential Care With Groundbreaking TreatmentNew Orleans, LA
Prof. John G. Gribben, MD, DSc
Barts Cancer Institute
Barts and The London School of Medicine, Queen Mary, University of London
London, England, United Kingdom
3:00 PM CST
MYELODYSPLASTIC SYNDROMES
The Future Is Now in MDS: Integrating Innovative, Risk-Adapted Therapies Into Patient ManagementNew Orleans, LA
Guillermo Garcia-Manero, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas
5:45 PM PST
GI MALIGNANCIES
Seek and You Will Find in Advanced GI Cancers: Identifying and Targeting Uncommon but Actionable Genomic AlterationsSan Francisco, CA
Vivek Subbiah, MD
The University of Texas MD Anderson Cancer Center
MD Anderson Cancer Center Network
Houston, Texas
5:45 PM PST
HCC
The HCC Revolution Continues: Exploring Evidence-Based Treatment Selection and Sequencing in Advanced Disease and Beyond
Ghassan Abou-Alfa, MD, MBA
Memorial Sloan Kettering Cancer Center
New York, New York
6:00 PM EST
CHRONIC LYMPHOCYTIC LEUKEMIA
Fine-Tuning the Wave of Innovation in CLL: Personalized Models for Upfront and Sequential Care With Groundbreaking TreatmentNew York, NY
Nicole Lamanna, MD
Herbert Irving Comprehensive Cancer Center
New York-Presbyterian/Columbia University Medical Center
New York, New York
5:30 PM PST
BILIARY CANCER
Getting Personal With Advanced BTC: Insights on Personalizing Upfront and Sequential Care With Immunotherapy and Targeted AgentsSan Francisco, CA
Rachna T. Shroff, MD, MS
University of Arizona Cancer Center (UACC)
UA College of Medicine – Tucson (UA COM-T)
Tucson, Arizona
12:10 PM PST
NSCLC
Realizing the Promise of Perioperative Immunotherapy in Resectable NSCLC: How to Modernize Best Practices Based on New Evidence and Better Multidisciplinary AlliancesSan Diego, CA
Nasser Altorki, MD
Weill Cornell Medicine
Meyer Cancer Center of Weill Cornell
New York, New York
Jonathan D. Spicer, MD, PhD, FRCSC
McGill University
Montreal General Hospital
Montreal, Quebec, Canada
12:40 PM PST
NSCLC
EGFR-Targeted Therapy for Early-Stage NSCLC: What Thoracic Surgeons Need to KnowSan Diego, CA
Catherine Shu, MD
Columbia University Medical Center
New York, New York
1:00 PM EST
VENO-OCCLUSIVE DISEASE
New Rules for VOD/SOS: Modern Risk Assessment, Diagnostic Principles, and Innovative TreatmentOrlando, FL
Prof. Mohamad Mohty
Saint-Antoine Hospital
Sorbonne University
Paris, France
Christine N. Duncan, MD
Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Boston Children’s Hospital
Harvard Medical School
Boston, Massachusetts
1:00 PM EST
MULTIPLE MYELOMA
Hitting the BCMA Target in Multiple Myeloma: Insights on CAR-T Therapy and Innovative Antibody OptionsOrlando, FL
Thomas G. Martin, III, MD
UCSF Helen Diller Family Comprehensive Cancer Center
The University of California, San Francisco
San Francisco, California
Krina Patel, MD, MSc
The University of Texas MD Anderson Cancer Center
Houston, Texas
7:30 AM EST
GRAFT-VERSUS-HOST DISEASE
Overcoming GVHD Is the Key to Better HCT Outcomes: Guidance on Managing Acute and Chronic DiseaseOrlando, FL
Stephanie Lee, MD, MPH
Fred Hutch Cancer Center
University of Washington
Seattle, Washington
12:45 PM EST
ACUTE MYELOID LEUKEMIA
The Convergence of Innovative Therapy and AlloHCT in AML: Applying Current Evidence to Improve OutcomesOrlando, FL
James M. Foran, MD, FRCPC
Mayo Clinic Cancer Center
Jacksonville, Florida
Jessica K. Altman, MD
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Chicago, Illinois
6:45 PM PST
RCC
Breaking New Ground in RCC Management: Expert Guidance on Leveraging Therapeutic StrategiesSan Francisco, CA
Sumanta Kumar Pal, MD, FASCO
City of Hope Comprehensive Cancer Center
Duarte, California
6:45 PM PST
BLADDER CANCER
Fresh Perspectives on Moving Toward Personalized Care for Bladder Cancer: Tips, Tools, and Strategies for Leveraging the Latest Advancements Across the Disease SpectrumSan Francisco, CA
Matthew I. Milowsky, MD, FASCO
University of North Carolina at Chapel Hill
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina
6:15 PM PST
PROSTATE CANCER
Expanding Use of Hormonal Therapeutic Strategies in Prostate Cancer: Clinical Evidence and Practical Considerations for Individualized, Patient-Centered CareSan Francisco, CA
Matthew R. Smith, MD, PhD
Harvard Medical School
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
6:00 PM PST
NSCLC
Refining Precision Decisions in NSCLC With Common and Less Common EGFR Mutations: Navigating Testing and Treatment Throughout the Disease ContinuumSanta Monica, CA
Natasha B. Leighl, MD, MMSc, FRCPC, FASCO
Princess Margaret Cancer Centre
PMC Foundation
University of Toronto
Dalla Lana School of Public Health
Toronto, Ontario, Canada
7:30 AM PST
MULTIPLE SCLEROSIS
BTK Inhibition as an MS Treatment Modality: Where Do We Stand and Where Are We Headed?San Diego, CA
Benjamin M. Greenberg, MD, MHS
University of Texas Southwestern Medical Center
Dallas, Texas
Jiwon Oh, MD, PhD, FRCPC
St. Michael’s Hospital
University of Toronto
Keenan Research Centre of the Li Ka Shing Knowledge Institute
Toronto, Ontario, Canada
6:00 PM PST
NSCLC
Peer Pressure: How Well Do You Know Your ADCs? Answers to Key Questions About Antibody–Drug Conjugates in NSCLCSanta Monica, CA
Benjamin Levy, MD
Johns Hopkins School of Medicine
Johns Hopkins Sidney Kimmel Cancer Center (SKCC) at Sibley Memorial Hospital
Washington, District of Columbia
12:45 PM EST
BREAST CANCER
A Practical Case-Based Approach to Navigating the Complexities of Advanced- and Early-Stage HR+/HER2- Breast CancerAtlanta, GA
Joyce O’Shaughnessy, MD
Baylor University Medical Center
Dallas, Texas
6:15 AM CST
HYPERTROPHIC CARDIOMYOPATHY (HCM)
Loosening the Grip of Hypertrophic Cardiomyopathy: Updated Strategies for Timely Diagnosis and Disease-Modifying TreatmentNew Orleans, LA
Neal K. Lakdawala, MD
Brigham and Women’s Hospital
Harvard Medical School
Boston, Massachusetts
Anjali Tiku Owens, MD
University of Pennsylvania Perelman School of Medicine
Philadelphia, Pennsylvania
6:00 AM CDT
BREAST CANCER
A New View of the Spectrum of HER2 Expression and Significance of HER2 Low in Breast Cancer: Exploring the Biology and Updating Best Practices for Testing and TreatmentNew Orleans, LA
Stuart J. Schnitt, MD
Dana-Farber/Brigham and Women’s Cancer Center
Harvard Medical School
Boston, Massachusetts
Paolo Tarantino, MD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts
6:30 AM CDT
IMMUNO-ONCOLOGY BIOMARKERS
Gaining Confidence in Predicting and Assessing Response to Cancer Immunotherapies: Practical Strategies for Biomarker Testing and Pathologic Response AssessmentNew Orleans, LA
Lynette M. Sholl, MD
Brigham and Women’s Hospital
Harvard Medical School
Boston, Massachusetts
7:00 PM CDT
PRURIGO NODULARIS
Moving Beyond Off-Label Management in Prurigo Nodularis: Exploring New Treatment OptionsNew Orleans, LA
Sarina B. Elmariah, MD, PhD, MPH
University of California
San Francisco, California
Shawn Kwatra, MD
Johns Hopkins Itch Center
Johns Hopkins University School of Medicine
Baltimore, Maryland